Combination therapy of semaphorin 4D blockade (SEMA4D) and DC1 therapy

A combination therapy of HER2-pulsed dendritic cells with SEMA4D inhibitors enhances anti-tumor immune responses, addressing the inadequacies of current breast cancer treatments by improving response rates and reducing tumor vascular leakage.

JP7579284B2Active Publication Date: 2024-11-07VACCINEX INC +1
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
JP2021576300
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2019-06-21
Filing Date
2020-06-19
Publication Date
2024-11-07
Estimated Expiration
2040-06-19

AI Technical Summary

Technical Problem

Current treatments for HER2-positive ductal carcinoma in situ (DCIS) and invasive breast cancer (IBC) are inadequate, leading to undertreatment or overtreatment, and there is a need for more effective immunotherapeutic strategies to address tumor resistance and reduce mortality in breast cancer patients, particularly those with HER2 overexpression.

Method used

A combination therapy using oncodriver-pulsed dendritic cells, specifically HER2-pulsed dendritic cells, in conjunction with immunomodulatory molecule inhibitors such as semaphorin 4D (SEMA4D) or VEGF inhibitors, to enhance anti-tumor immune responses and target the tumor vasculature.

Benefits of technology

The therapy restores anti-HER2 Th1 immune responses, improves pathological complete response rates, and reduces tumor vascular leakage, effectively inhibiting cancer progression and metastasis, while minimizing adverse effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007579284000003
    Figure 0007579284000003
  • Figure 0007579284000004
    Figure 0007579284000004
  • Figure 0007579284000005
    Figure 0007579284000005
Patent Text Reader

Abstract

Disclosed are compositions comprising pulsed dendritic cells and an immunomodulatory molecule inhibitor, as well as methods comprising their administration, for the treatment of cancer. TIFF2022537453000004.tif91128
Need to check novelty before this filing date? Find Prior Art

Description

[Background technology]

[0001] background The aggressive properties of various cancer types are primarily driven by oncodrivers such as HER2, HER3, EGFR, and c-MET, which are critically involved in cell growth, proliferation, survival, and differentiation. Overexpression of these oncodrivers is associated with poor prognosis and is a key player in tumor cell resistance to targeted therapy. Ductal carcinoma in situ (DCIS) is an early type of BC stage 0 that affects approximately 60,000 women annually in the United States. These women are at high risk (25%) of having another BC event. Despite a favorable prognosis and a survival rate of 98%, the incidence rate is higher in women under 40 years of age, African American women, and those with estrogen receptor-negative (ER)-positive breast cancer. neg ) There is some suggestion that women, including those with DCIS, have a 7-15% chance of dying from subsequent invasive breast cancer (BC), possibly due to leakage of disseminated cancer cells (DCC) before IBC is clinically detected. Approximately 33-50% of high-grade DCIS lesions express HER2 protein, with another third showing intermediate HER2 expression. We have found that these women with HER2 DCIS usually have T1a / b (T1a being tumors smaller than 5 mm); T1b being tumors between 5 mm and 1 cm. For example, the American Joint Committee on Cancer (AJCC) Staging Manual-8 thEdition, Amin, MB, et al. Eds., Springer Nature (2017) showed that IBC components were significantly more likely to be identified in DCIS with T1b IBC and were at higher risk of ipsilateral breast recurrence. Patients with T1b IBC have an increased risk of subsequent mortality of 20-30%, and therefore most of these women are offered adjuvant chemotherapy with trastuzumab to reduce the risk. Although effective, even weekly paclitaxel and trastuzumab can cause neurological, cardiac, cognitive, and other morbidity. Many of these patients present with larger areas of DCIS intermingled with T1a / b IBC and undergo even more intensive chemotherapy regimens such as PTCH, as the T stage of IBC can be difficult to identify. Many patients also require mastectomy, as extensive DCIS does not always respond to neoadjuvant therapy. If these tumors are also estrogen receptor positive, patients also undergo an additional 5 years of treatment with antiestrogens, further increasing morbidity. In summary, some HER2 DCIS patients are potentially undertreated, placing them at higher risk for subsequent breast events and even slightly increased mortality, and T1a / b patients are not uncommonly overtreated. Existing targeted strategies are poorly effective, so there is a need for compelling immunotherapeutic strategies. [Prior art documents] [Non-patent literature]

[0002] [Non-Patent Document 1] American Joint Committee on Cancer (AJCC) Staging Manual-8th Edition, Amin, MB, et al. Eds., Springer Nature (2017) Summary of the Invention

[0003] overview Methods and compositions are disclosed that relate to novel combination therapies comprising onco-driver pulsed dendritic cells and immune regulatory molecule inhibitors.

[0004] In one aspect, disclosed herein is an anti-cancer combination therapy comprising at least one dendritic cell pulsed with an onco-driver (such as, for example, human epidermal growth factor receptor (HER) 2 (HER2)) and at least one inhibitor of an immune-modulatory molecule (such as, for example, semaphorin (SEMA) 4D (SEMA4D) or VEGF), where the immune-modulatory molecule being inhibited affects the vasculature of a tumor.

[0005] In one aspect, disclosed herein is a method of treating, preventing, ameliorating, and / or inhibiting cancer in a subject (e.g., including breast cancer (including triple-negative breast cancer, metastatic breast cancer (MBC), ductal carcinoma in situ (DCIS), and invasive breast cancer (IBC)), melanoma, colorectal cancer, pancreatic cancer, prostate cancer, bladder cancer, ovarian cancer, and gastric cancer, and including primary and distant tumors), comprising administering an anti-cancer combination therapy of any of the aforementioned aspects. Thus, disclosed herein is a method of treating cancer in a subject, comprising administering to the subject at least one dendritic cell pulsed with an onco-driver (e.g., human epidermal growth factor receptor (HER) 2 (HER2)), and at least one inhibitor of an immunomodulatory molecule (e.g., semaphorin (SEMA) 4D (SEMA4D) or VEGF), wherein the inhibited immunomodulatory molecule affects the vasculature of the tumor.

[0006] Also disclosed are anti-cancer combination therapy methods for treating, preventing, ameliorating, and / or inhibiting any of the aforementioned aspects of cancer, in which at least one immune modulatory molecule inhibitor is administered systemically and / or onco-driver pulsed dendritic cells are administered intratumorally.

[0007] Also disclosed herein in one aspect is an anti-cancer combination therapy method for treating, preventing, ameliorating, and / or inhibiting cancer of any of the aforementioned aspects, wherein onco-driver pulsed dendritic cells are activated with IL-12 prior to administration.

[0008] Also disclosed herein is an anti-cancer combination therapy method for treating, preventing, alleviating, and / or inhibiting any of the above-mentioned aspects of cancer, wherein at least one immunomodulatory molecule inhibitor comprises an antibody or functional fragment thereof that binds to SEMA4D (also referred to herein as CD100), such as anti-SEMA4D antibody Mab 67 or VX15 / 2503 (Pepinemab).See, for example, U.S. Patent No. 8,496,938, which is incorporated herein by reference.

[0009] Also disclosed herein, in one aspect, is an anti-cancer combination therapy method for treating, preventing, ameliorating, and / or inhibiting cancer of any of the aforementioned aspects, wherein dendritic cells are harvested from a subject and pulsed with an onco-driver ex vivo.

[0010] The pulsed dendritic cells are administered at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 18, 24, 30, 36 hours, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 21, 28, 30, 31, 45 days, 2, 3, 4, 5, or 6 months prior to administration of at least one immunomodulatory molecule inhibitor; are administered simultaneously with at least one immunomodulatory molecule inhibitor; or are administered at least one immunomodulatory molecule inhibitor. Also disclosed herein are anti-cancer combination therapy methods for treating, preventing, ameliorating, and / or inhibiting cancer of any of the aforementioned aspects, wherein the anti-cancer combination therapy method comprises administering at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 18, 24, 30, 36 hours, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 21, 28, 30, 31, 45 days, 2, 3, 4, 5, or 6 months prior to administration of the pulsed dendritic cells.

[0011] Also disclosed herein is an anti-cancer combination therapy method of treating, preventing, ameliorating, and / or inhibiting cancer of any of the foregoing aspects, in which at least one pulsed dendritic cell is administered at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 days, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, or 24 times per day, or at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, or 14 times per week.

[0012] Also disclosed herein are anti-cancer combination therapy methods of treating, preventing, ameliorating, and / or inhibiting cancer of any of the aforementioned aspects, wherein at least one immune modulatory molecule inhibitor is administered at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 times per day, or at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 times per week for at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 days, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 weeks. [The present invention 1001] An anti-cancer combination therapy comprising at least one dendritic cell pulsed with an oncodriver and at least one immunomodulatory molecule inhibitor, wherein the immunomodulatory molecule comprises semaphorin 4D or VEGF. [The present invention 1002] The anti-cancer combination therapy of the present invention 1001, wherein the oncodriver is human epidermal growth factor receptor (HER) HER2. [The present invention 1003] The anti-cancer combination therapy of the present invention 1001 or 1002, wherein the onco-driver pulsed dendritic cells are activated with IL-12 prior to administration. [The present invention 1004] The anti-cancer combination therapy of any of claims 1001 to 1003, wherein the immunomodulatory molecule inhibitor comprises an antagonist antibody that specifically binds to SEMA4D or VEGF. [The present invention 1005] The anti-cancer combination therapy of the present invention 1004, wherein the antagonist antibody that specifically binds to SEMA4D comprises pepinemab. [The present invention 1006] The anti-cancer combination therapy of any of claims 1001 to 1005, wherein at least one immunomodulatory inhibitor is formulated for systemic administration. [The present invention 1007] The anti-cancer combination therapy of any of claims 1001 to 1006, wherein at least one dendritic cell pulsed with an onco-driver is formulated for intratumoral administration. [The present invention 1008] The anti-cancer combination therapy of any of claims 1001 to 1007, wherein at least one dendritic cell pulsed with an onco-driver is obtained by collecting dendritic cells from a subject to be treated with the anti-cancer combination therapy, and is pulsed with an onco-driver ex vivo. [The present invention 1009] The anti-cancer combination therapy of any of claims 1001 to 1008, wherein the cancer is breast cancer, melanoma, colorectal cancer, pancreatic cancer, prostate cancer, bladder cancer, ovarian cancer, gastric cancer, any combination thereof, or any metastasis thereof. [The present invention 1010] At least one dendritic cell pulsed with an onco-driver for use in treating cancer in a subject in combination with at least one immune modulatory molecule inhibitor, comprising: The immunomodulatory molecule comprises semaphorin 4D or VEGF; For use, at least one dendritic cell pulsed with an onco-driver. [The present invention 1011] At least one dendritic cell pulsed with an onco-driver for use according to the present invention 1010, wherein the onco-driver is human epidermal growth factor receptor (HER) HER2. [The present invention 1012] At least one dendritic cell pulsed with an onco-driver for use according to the invention 1010 or 1011, wherein the onco-driver pulsed dendritic cell is activated with IL-12 prior to administration. [The present invention 1013] At least one dendritic cell pulsed with an onco-driver for use according to any of claims 1010 to 1012, wherein the immune modulatory molecule inhibitor comprises an antagonist antibody that specifically binds to SEMA4D or VEGF. [The present invention 1014] At least one dendritic cell pulsed with an onco-driver for use according to the present invention 1013, wherein the antagonist antibody that specifically binds to SEMA4D comprises pepinemab. [The present invention 1015] At least one dendritic cell pulsed with an onco-driver for use according to any of claims 1010 to 1014, wherein at least one immunomodulatory inhibitor is formulated for systemic administration. [The present invention 1016] At least one dendritic cell pulsed with an onco-driver, for use in any of the present inventions 1010 to 1015, wherein the at least one dendritic cell pulsed with an onco-driver is formulated for intratumoral administration. [The present invention 1017] At least one dendritic cell pulsed with an onco-driver, for use according to any of the present inventions 1010 to 1016, wherein the at least one dendritic cell pulsed with an onco-driver is obtained by harvesting dendritic cells from a subject to be treated with an anti-cancer combination therapy and is pulsed with an onco-driver ex vivo. [The present invention 1018] At least one dendritic cell pulsed with an onco-driver for use according to any of claims 1010 to 1017, wherein the cancer is breast cancer, melanoma, colorectal cancer, pancreatic cancer, prostate cancer, bladder cancer, ovarian cancer, gastric cancer, any combination thereof, or any metastasis thereof. [Brief description of the drawings]

[0013] The accompanying drawings, which are incorporated in and constitute a part of this specification, illustrate several embodiments and, together with the description, illustrate the disclosed compositions and methods. [Figure 1A]Figures 1A, 1B, 1C, and 1D show the progressive loss of anti-oncodriver Th1 responses with progression of oncodriver-expressing breast disease, and the association of anti-oncodriver immunity with improved clinical outcomes. Figure 1A shows loss of HER-2 Th1 responses with progression of HER-2 positive disease; Figure 1B shows that vaccines help restore anti-HER2 Th1 immunity, but standard treatments do not; Figure 1C shows that Th1 immunity to HER-2 predicts clinical response to standard treatment; and Figure 1D shows that HER-2 Th1 responsiveness predicts disease-free survival after standard treatment. Acronyms: DCIS: ductal carcinoma in situ; IBC: invasive breast cancer; Tx: treatment; pCR: pathological complete response; ER: estrogen receptor; TNBC: triple negative breast cancer. [Figure 1B] See legend to Figure 1A. [Figure 1C] See legend to Figure 1A. [Figure 1D] See legend to Figure 1A. [Diagram 2] Figures 2A, 2B, and 2C show that short-term anti-estrogen therapy concomitant with DC1 vaccination improves pCR rates (Figure 2A) and anti-HER2 Th1 immunity (Figure 2B) in subjects with hormone-dependent (ER-positive) disease, and that pathologic complete response (pCR) predicts long-term subsequent breast event (SBE) freedom in all vaccinated subjects (Figure 2C). [Figure 3-1]3A-3G show that intratumoral DC1 in combination with anti-SEMA4D antibody induced tumor regression in a HER2-positive TUBO model. Figure 3A: SEMA4D expression in TUBO cells measured by immunohistochemistry compared to IgG isotype control antibody; Figure 3B: Intratumoral class II HER2 peptide-pulsed DC1 intratumoral injection in combination with anti-SEMA4D antibody administered intraperitoneally in a single tumor model (Figure 3B1) and survival curves (Figure 3B2); Figure 3C: Efficacy of intratumoral DC1 in combination with anti-SEMA4D in a bilateral model (Figure 3C1 and Figure 3C2); TUBO-bearing mice were treated with either non-pulsed or class II HER2 peptide-pulsed activated DC1 alone or in combination with anti-SEMA4D antibody; Figure 3D: IHC staining of SEMA4D in DCIS and IBC patients, numbers indicate number of patients with positive SEMA4D staining; Figure 3E: Myeloid-derived suppressor cell (MDSC) infiltration per mg of tumor treated with DC1 alone, anti-SEMA4D alone, or in combination; Figure 3F: CD4 T cell infiltration; FIG. 3G: CD4 T cell infiltration in lymph nodes (absolute counts). [Figure 3-2] See description of Figure 3-1. [Figure 3-3] See description of Figure 3-1. [Diagram 3-4] See description of Figure 3-1. [Figure 4]Figures 4A, 4B, and 4C show that T cells from HER2-DC1+aSema4D-treated mice were superior in proliferation, function, and specificity compared to T cells from HER2-DC1-only vaccinated mice. Figure 4A: In vitro CD4 T cell expansion fold expansion after 3 weeks. CD4+ T cells were isolated from splenocytes isolated from vaccinated mice using EASYSEP™ (Stemcell Technologies), co-cultured with HER2 peptide-pulsed DC1, and then expanded with IL-2 and IL-7 for 3 weeks; Figure 4B: Expanded T cells from DC1+anti-SEMA4D-treated mice were more antigen-specific for HER2 / neu peptide antigens p5, p435, and p1209 compared to T cells from DC1-vaccinated mice; Figure 4C: Expanded T cell cumulative IFN-γ response. [Diagram 5] Figures 5A, 5B, and 5C show detection of DCC in neu transgenic mice. Figure 5A: Flow staining of DCC in bone marrow (BM) with expression of cytokeratin 8 / 18 and HER2; Figure 5B: Immunofluorescence staining of HER2, cytokeratin, and ki67; Figure 5C: Detection of DCC in different organs of neu T mice. [Figure 6A] Figures 6A, 6B, 6C, and 6D show that HER2 peptide-DC1 vaccine prevents mammary tumor development, induces senescence, and eliminates DCCs in NeuT mice. Figure 6A: Immunofluorescence staining of bone marrow DCCs from control and DC1 vaccinated neu T mice. [Figure 6B] Figures 6A, 6B, 6C, and 6D show that the HER2 peptide-DC1 vaccine prevents mammary tumor development, induces senescence, and eliminates DCC in NeuT mice. Figure 6B: Detectable tumor masses in the mammary gland using ultrasound. [Figure 6C] Figures 6A, 6B, 6C, and 6D show that HER2 peptide-DC1 vaccine prevents breast tumor development, induces senescence, and eliminates DCC in NeuT mice. Figure 6C: Percentage of DCC in bone marrow measured using flow cytometry. [Figure 6D] Figures 6A, 6B, 6C, and 6D show that HER2 peptide-DC1 vaccine prevents breast tumor development, induces senescence, and eliminates DCCs in NeuT mice. Figure 6D: Detection of senescent cells using β-gal assay. Representative images after β-gal staining. [Figure 7] Figures 7A and 7B show that HER2 peptide-pulsed DC1 vaccine and anti-SEMA4D treatment induce B cell infiltration in the mammary gland and CD4+ T cell infiltration in the bone marrow of NeuT mice. Figure 7A: 8-week-old NeuT mice were treated with HER2 peptide-pulsed DC1 vaccine (2 injections per week for 3 weeks) or anti-SEMA4D antibody. At week 16, mice were sacrificed and mammary glands were harvested. Single cell suspensions of mammary glands were prepared and stained for CD19-positive B cells and then analyzed by flow cytometry. Elevated levels of CDa19+ B cells were observed in DC1-vaccinated and anti-SEMA4D-treated mice compared to untreated controls; Figure 7B: Bone marrow cells from control and DC1-vaccinated NeuT mice were stained for CD4 and CD8 T cell markers and analyzed by flow cytometry. Increased numbers of CD4 and CD8 T cells were observed in the bone marrow of DC1-vaccinated NeuT mice compared to untreated control mice. [Figure 8A] Figures 8A, 8B, 8C, 8D, and 8E show that dual blockade of HER2 and HER3 in combination with Th1 cytokines mediates tumor senescence and apoptosis in SK-BR-3 breast cancer cells. Figure 8A: Dual blockade of HER2 / HER3 in SK-BR-3 cells in combination with Th1 cytokines TNF-α and IFN-γ increased the number of senescent cells and higher SA-β-gal staining was observed in the cells. [Figure 8B]Figures 8A, 8B, 8C, 8D, and 8E show that dual blockade of HER2 and HER3 in combination with Th1 cytokines mediates tumor senescence and apoptosis in SK-BR-3 breast cancer cells. Figure 8B: SK-BR-3 cells untreated (1), treated with TNF-α and IFN-γ (2), or treated with trastuzumab (Herceptin, H (TZm)) and pertuzumab (Per) (3), or treated with TNF-α, IFN-γ, and TZm and Per (4). [Figure 8C] Figures 8A, 8B, 8C, 8D, and 8E show that dual blockade of HER2 and HER3 in combination with Th1 cytokines mediates tumor senescence and apoptosis in SK-BR-3 breast cancer cells. Figure 8C: Western blot analysis of SK-BR-3 cells treated with Th1 cytokines in combination with Tzm and Per induced expression of cyclin-dependent kinase 4 inhibitor B, also known as p15INK4b, and cleaved caspase-3 (treatment numbers as in panel B). [Figure 8D] Figures 8A, 8B, 8C, 8D, and 8E show that dual blockade of HER2 and HER3 in combination with Th1 cytokines mediates tumor senescence and apoptosis in SK-BR-3 breast cancer cells. Figures 8D and 8E: Apoptosis by Annexin V / PI staining (treatment numbers are the same for panels D and E). [Figure 8E] Figures 8A, 8B, 8C, 8D, and 8E show that dual blockade of HER2 and HER3 in combination with Th1 cytokines mediates tumor senescence and apoptosis in SK-BR-3 breast cancer cells. Figures 8D and 8E: Apoptosis by Annexin V / PI staining (treatment numbers are the same for panels D and E). [Figure 9]Figures 9A, 9B, and 9C show that Th1 cytokines TNF-α and IFN-γ induce senescence and apoptosis in trastuzumab- and pertuzumab-resistant breast cancer cells. Figure 9A: HCC-1419 and JIMT-1 cells; 1) untreated; 2) treated with TNF-α and IFN-γ; 3) treated with TZm and Per, or 4) treated with TNF-α, IFN-γ, Tzm, and Per. Figure 9A. % of SA-β-gal positive cells; Figure 9B: Western blot analysis of p15INKb and cleaved caspase-3 expression of HCC-1419 after treatment; and Figure 9C: Western blot analysis of JIMT-1 cells. Vinculin was used as a control. [Figure 10] Figures 10A and 10B show HER2-specific CD4+ Th1-mediated senescence and apoptosis of HER2-overexpressing human breast cancer cells. Figure 10A: SK-BR-3 cells co-cultured with CD4+ T cells alone (CD4+ only (1)), CD4+ T cells + HER2 peptide-pulsed immature dendritic cells (CD4+ IDC H (2)), CD4+ T cells + HER2 peptide-pulsed mature dendritic cells (CD4+ DC H (3)), or CD4+ DC H with trastuzumab (Tzm) and pertuzumab (Per) (4), or CD4+ T cells + irrelevant peptide-pulsed mature dendritic cells (BRAF (CD4+ DC B) (5); or survivin (CD4+ DC S) (6)) with Tzm and Per. Figure 10B: Western blot analysis of tumor cells showed increased p15INK4b and cleaved caspase-3 expression when co-cultured with DC H / CD4+ T cells in the presence of Tzm and Per, suggesting induction of senescence and apoptosis, respectively, in DC B, DC S, and iDC H groups, but not in the latter. Vinculin was used as a loading control. [Figure 11] We show that IFN-γ administered subcutaneously twice weekly with weekly taxol and standard-dose trastuzumab and pertuzumab was safe and produced disease stabilization with partial responses in patients with first-line metastatic breast cancer. [Figure 12]Figures 12A, 12B, 12C, and 12D show immunohistochemical staining of lymphocytic infiltration before and after DC1 vaccination in DCIS. Figures 12A and 12B show areas of dense lymphocytic infiltration; Figures 12C and 12D show areas of little or no response. [Figure 13] 1 shows lymphocyte accumulation before and after DC1 vaccination in DCIS, with CD4, CD8, and CD20 infiltration shown. [Figure 14] 1 shows lymphocytic infiltration within DCIS ducts following DC1 vaccination. [Figure 15] Figure 15A and Figure 15B show that combination therapy of intratumoral DC1 and anti-SEMA4D improves tumor vascularization. Figure 15A: Slope of DCE-MRI curve calculated after iv administration of Gadavist (gadolinium-based MRI contrast agent, 0.2 mmol / kg). Regardless of tumor volume, combination treatment shows a smaller slope, indicating less vascular leakage; Figure 15B: DCE-MRI curve of TUBO tumor showing that combination treatment has a smaller DCE curve. Data are expressed as relative values ​​(to the first point of the curve) to show reliable comparison between tumors. [Figure 16] CEST MRI (tumor pH) maps of TUBO tumors treated with anti-SEMA4D. From right to left: T2 weighted image representing the ROI, pH map (insert shows mean pH value and its standard deviation), and histogram representing calculated pH value of all pixels. [Figure 17-1]Figures 17A-F show that CD4+ T cells are required for anti-SEMA4D activity. Figure 17A: Mean tumor size (mm2) in a murine Her2 TUBO breast cancer model over time after treatment with Her2DC1, anti-SEMA4D, HER2 DC1+anti-SEMA4D, or control IgG. Figure 17B: Percent survival of Her2 TUBO tumor-bearing mice after treatment with Her2DC1, anti-SEMA4D, HER2 DC1+anti-SEMA4D, or control IgG. Figure 17C: Mean tumor size (mm2) of CD4-depleted Her2 TUBO tumor-bearing mice over time after treatment with Her2DC1, anti-SEMA4D, HER2 DC1+anti-SEMA4D, or no treatment. Figure 17D: Percent survival of CD4-depleted Her2 TUBO tumor-bearing mice after treatment with Her2DC1, anti-SEMA4D, HER2 DC1+anti-SEMA4D, or no treatment. Figure 17E: Tumor size (mm2) in individual Her2 TUBO tumor-bearing mice over time after treatment with Her2DC1, anti-SEMA4D, HER2 DC1+anti-SEMA4D, or control IgG. In control Balb / c mice, complete tumor regression is observed after treatment with anti-SEMA4D and anti-SEMA4D+Her2DC1 combinations. Figure 17F: Tumor size (mm2) in individual CD4-depleted Her2 TUBO tumor-bearing mice over time after treatment with Her2DC1, anti-SEMA4D, HER2 DC1+anti-SEMA4D, or control IgG. (17E, F: Tumor growth curves for each mouse are shown; CR=complete tumor regression; tumor volume<50 mm2.) (*p<0.05, **p<0.01). [Figure 17-2] See description of Figure 17-1. [Figure 18]Figures 18A-C show that Fc receptor gamma (FcRγ) is required for complete tumor regression after treatment with combination therapy. Figure 18A: Mean tumor size (mm2) in BALB / C.129V2(B6)-Fcer1gtm1Rav N12 tumor-bearing mice treated with HER2DC, anti-SEMA4D, HER2DC+anti-SEMA4D; or left untreated. Figure 18B: Percent survival of C.129P2(B6)-Fcer1gtm1Rav N12 tumor-bearing mice treated with HER2DC, anti-SEMA4D, HER2DC+anti-SEMA4D; or left untreated. Figure 18C: Tumor growth curves for each mouse are shown. Complete tumor regression is not observed in FcRγ-deficient mice. (*p<0.05, **p<0.01). [Figure 19] Figure 1. Interferon gamma (IFN-γ) is required for the antitumor activity of DC1, anti-SEMA4D, and combination therapy. Mean tumor size (mm2) in Balb / C IFN-γ knockout (KO) (C.129S7 (B6)-IFNgtm1Ts / J (IFN-γKO, Jackson Laboratories) mice bearing tumors generated from murine Her2 TUBO breast cancer cells is shown over time following treatment with HER2DC1, anti-SEMA4D, HER2 DC1 + anti-SEMA4D, or control IgG. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0014] Detailed Description Before the present compounds, compositions, articles, devices, and / or methods are disclosed and described, it is to be understood that they are not limited to specific synthetic methods or to specific recombinant biotechnology methods, unless otherwise specified, or to particular reagents, unless otherwise specified, and as such can, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting.

[0015] definition As used in this specification and the appended claims, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to "a pharmaceutical carrier" includes mixtures of two or more such carriers, and the like.

[0016] Ranges can be expressed herein as from "about" one particular value and / or to "about" another particular value. When such a range is expressed, another embodiment includes from one particular value and / or to the other particular value. Similarly, when values ​​are expressed as approximations by use of the antecedent "about," it will be understood that the particular value forms another embodiment. It will be further understood that the endpoints of each range are significant both in relation to the other endpoint and independently of the other endpoint. It is also understood that there are several values ​​disclosed herein, and that each value is also disclosed herein as "about" that particular value, in addition to the value itself. For example, if a value of "10" is disclosed, then "about 10" is also disclosed. It is also understood that when a value is disclosed, then "less than or equal to," "greater than or equal to," and possible ranges between values ​​are also disclosed, as would be well understood by one of ordinary skill in the art. For example, if a value of "10" is disclosed, then "less than or equal to 10" and "greater than or equal to 10" are also disclosed. It is also understood that throughout this application, data is provided in several different formats, and that this data represents the end and start points, and ranges of any combination of data points.For example, if a specific data point "10" and a specific data point 15 are disclosed, it is understood that values ​​greater than 10 and 15, greater than or equal to 10 and 15, less than 10 and 15, less than or equal to 10 and 15, and equal to 10 and 15 are considered to be disclosed, as well as between 10 and 15.It is also understood that each unit between two specific units is also disclosed.For example, if 10 and 15 are disclosed, 11, 12, 13, and 14 are also disclosed.

[0017] In this specification and in the claims that follow, reference will be made to a number of terms that shall be defined to have the following meanings.

[0018] "Optional" or "optionally" means that the subsequently described event or circumstance may or may not occur, and that the description includes instances when the event or circumstance occurs and instances when it does not occur.

[0019] "Reduction" can refer to any change that results in a smaller amount of a symptom, disease, composition, condition, or activity. A substance is also understood to reduce the genetic output of a gene when the genetic output of the gene product containing the substance is less compared to the output of the gene product without the substance. Similarly, for example, reduction can be a change in the symptoms of a disorder, such that the symptoms are less than those observed previously. Reduction can be any individual, median, or average reduction of a condition, symptom, activity, composition by a statistically significant amount. Thus, reduction can be 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100% reduction, as long as the reduction is statistically significant.

[0020] "Inhibit", "inhibiting" and "inhibition" refer to a decrease in an activity, response, condition, disease, or other biological parameter. This can include, but is not limited to, the complete disappearance of the activity, response, condition, or disease. It can also include, for example, a 10% decrease in the activity, response, condition, or disease compared to native or control levels. Thus, the decrease can be a decrease of 10, 20, 30, 40, 50, 60, 70, 80, 90, 100%, or any amount in between, compared to native or control levels.

[0021] "Reducing" or other forms of this word, such as "reducing" or "reducing", refers to the reduction of an event or characteristic (e.g., tumor growth). This is typically relative to some standard or expected value, which in turn is relative, but it is understood that it is not necessarily to refer to a standard or relative value. For example, "reducing tumor growth" refers to reducing the rate of tumor growth compared to a standard or control.

[0022] "Prevent" or other forms of this word, such as "preventing" or "prevention", means to stop a particular event or characteristic, stabilize or delay the occurrence or progression of a particular event or characteristic, or minimize the likelihood of a particular event or characteristic occurring. "Prevent" is typically more absolute than, for example, reduce, and does not require comparison to a control. As used herein, some things can be reduced but not prevented, but some things that are reduced can be prevented. Similarly, some things can be prevented but not reduced, but some things that are prevented can be reduced. When reduce or prevent is used, it is understood that the use of other words is expressly disclosed unless otherwise specifically indicated.

[0023] "Biocompatible" generally refers to a material and any metabolic or decomposition products thereof that are generally non-toxic to the recipient and cause no significant adverse effects in the subject.

[0024] "Comprising" is intended to mean that the composition, method, etc. includes the recited elements but does not exclude other elements. "Consisting essentially of" when used to define compositions and methods shall mean including the recited elements but excluding other elements of any essential importance to the combination. Thus, a composition consisting essentially of elements as defined herein does not exclude trace contaminants from isolation and purification methods, as well as pharma- ceutically acceptable carriers, e.g., phosphate buffered saline, preservatives, and the like. "Consisting of" shall mean excluding other components beyond trace elements, as well as substantial method steps for administering the compositions provided and / or claimed in this disclosure. Embodiments defined by each of these transition terms are within the scope of this disclosure.

[0025] A "control" is an alternative control or sample used in an experiment for comparison purposes. Controls can be "positive" or "negative."

[0026] An "effective amount" of an agent refers to an amount of the agent sufficient to provide a desired effect. The amount of an agent that is "effective" will vary from subject to subject, depending on many factors, such as the age and general condition of the subject, the particular agent or agents, etc. Thus, it is not always possible to specify a quantified "effective amount". However, the appropriate "effective amount" in any subject's case can be determined by one of ordinary skill in the art using routine experimentation. Similarly, as used herein, and unless otherwise specifically stated, an "effective amount" of an agent can also refer to an amount that covers both a therapeutically effective amount and a prophylactically effective amount. The "effective amount" of an agent required to achieve a therapeutic effect may vary depending on factors such as the age, sex, and weight of the subject. The dosing regimen can be adjusted to provide an optimal therapeutic response. For example, several divided doses may be administered daily, or the dose may be proportionally reduced as indicated by the exigencies of the therapeutic situation.

[0027] A "pharmaceutical acceptable" component can refer to a component that is not biologically or otherwise undesirable, i.e., the component can be incorporated into a pharmaceutical formulation provided by the present disclosure and administered to a subject as described herein without causing significant undesirable biological effects or interacting in a deleterious manner with any of the other components of the formulation in which it is included. When used in the context of human administration, the term generally means that the component has met the necessary standards of toxicological and manufacturing testing or is included in the inactive ingredients guide prepared by the U.S. Food and Drug Administration.

[0028] A "pharmaceutically acceptable carrier" (sometimes referred to as a "carrier") means a carrier or excipient useful in preparing a pharmaceutical or therapeutic composition that is generally safe and non-toxic, including carriers that are acceptable for veterinary and / or human pharmaceutical or therapeutic use. The term "carrier" or "pharmaceutically acceptable carrier" can include, but is not limited to, phosphate buffered saline, water, emulsions (such as oil / water or water / oil emulsions), and / or various types of wetting agents. As used herein, the term "carrier" includes, but is not limited to, any excipient, diluent, filler, salt, buffer, stabilizer, solubilizer, lipid, stabilizer, or other material that is well known in the art for use in pharmaceutical formulations and as further described herein.

[0029] "Pharmacologically active" (or simply "active"), as in "pharmacologically active" derivative or analog, may refer to a derivative or analog (e.g., a salt, ester, amide, conjugate, metabolite, isomer, fragment, etc.) that has the same type of pharmacological activity as the parent compound, and to about the same extent.

[0030] "Polymer" refers to a relatively high molecular weight organic compound, natural or synthetic, whose structure can be represented by repeating small units, monomers. Non-limiting examples of polymers include polyethylene, rubber, and cellulose. Synthetic polymers are typically formed by addition or condensation polymerization of monomers. The term "copolymer" refers to a polymer formed from two or more different repeating units (monomer residues). By way of example and not limitation, a copolymer can be an alternating copolymer, a random copolymer, a block copolymer, or a graft copolymer. It is also contemplated that in certain aspects, the various block segments of a block copolymer may themselves comprise copolymers. The term "polymer" encompasses all forms of polymers, including but not limited to natural polymers, synthetic polymers, homopolymers, heteropolymers or copolymers, addition polymers, and the like.

[0031] As provided herein, a "binding molecule" or "antigen-binding molecule" (e.g., an antibody or an antigen-binding fragment thereof) in its broadest sense refers to a molecule that specifically binds to an antigenic determinant. In one embodiment, the binding molecule specifically binds to an immunomodulatory molecule (e.g., a transmembrane SEMA4D (CD 100) polypeptide of about 150 kDa or a soluble SEMA4D polypeptide of about 120 kDa, etc.). In another embodiment, the binding molecule is an antibody or an antigen-binding fragment thereof, such as MAb 67 or pepinemab.

[0032] "Therapeutic agent" refers to any composition that has a beneficial biological effect. Beneficial biological effects include both therapeutic effects, such as the treatment of disorders or other undesirable physiological conditions, and prophylactic effects, such as the prevention of disorders or other undesirable physiological conditions (e.g., non-immunogenic cancers). The term also encompasses pharmaceutically acceptable, pharmacologically active derivatives of the beneficial agents specifically mentioned herein, including, but not limited to, salts, esters, amides, proagents, active metabolites, isomers, fragments, analogs, and the like. Then, when the term "therapeutic agent" is used, or when a particular agent is specifically identified, it should be understood that the term includes the agent itself, as well as pharmaceutically acceptable, pharmacologically active salts, esters, amides, proagents, conjugates, active metabolites, isomers, fragments, analogs, and the like.

[0033] A "therapeutically effective amount" or "therapeutically effective dose" of a composition (e.g., a composition comprising an agent) refers to an amount that is effective to achieve a desired therapeutic outcome. In some embodiments, the desired therapeutic outcome is the management of type I diabetes. In some embodiments, the desired therapeutic outcome is the management of obesity. The therapeutically effective amount of a given therapeutic agent will typically vary in relation to factors such as the type and severity of the disorder or disease being treated, as well as the age, sex, and weight of the subject. The term may also refer to the amount of therapeutic agent or the delivery rate of the therapeutic agent (e.g., amount over time) effective to promote a desired therapeutic effect, such as pain relief. The exact desired therapeutic effect will vary depending on the condition to be treated, the tolerance of the subject, the agent and / or agent formulation to be administered (e.g., potency of the therapeutic agent, concentration of the agent in the formulation, etc.), as well as various other factors recognized by those skilled in the art. In some cases, the desired biological or medical response is achieved after administering multiple doses of the composition to the subject over a period of days, weeks, or years.

[0034] Throughout this application, various publications are referenced. The disclosures of these publications in their entireties are hereby incorporated by reference into this application in order to more fully describe the state of the art to which this pertains. The references disclosed are also individually and specifically incorporated by reference herein for the material contained in them that is discussed in the sentence in which the reference is relied upon.

[0035] composition Disclosed are the components to be used to prepare the disclosed compositions, and the compositions themselves to be used in the methods disclosed herein. These and other materials are disclosed herein, and when combinations, subsets, interactions, groups, etc. of these materials are disclosed, it is understood that each of the various individual and collective combinations and permutations of these compounds are specifically contemplated and described herein, although specific reference may not be explicitly disclosed. For example, when a particular dendritic cell pulsed with a particular immunomodulatory molecule inhibitor or oncodriver is disclosed and discussed, and several modifications that can be made to several molecules including the immunomodulatory molecule inhibitor or oncodriver-pulsed dendritic cell are discussed, unless specifically indicated otherwise, any and all combinations and permutations of the immunomodulatory molecule inhibitor or oncodriver-pulsed dendritic cell and possible modifications are specifically contemplated. Thus, if classes of molecules A, B, and C are disclosed, as well as classes of molecules D, E, and F, and an example of a combination molecule AD is disclosed, each is individually and collectively contemplated, even if each is not individually listed, and the combinations AE, AF, BD, BE, BF, CD, CE, and CF are considered to be disclosed. Similarly, any subset or combination of these is also disclosed. Thus, for example, the subgroups AE, BF, and CE are considered to be disclosed. This concept applies to all aspects of this application, including but not limited to steps in the methods of making and using the disclosed compositions. Thus, when there are various additional steps that can be performed, it is understood that each of these additional steps can be performed with any particular embodiment or combination of embodiments of the disclosed methods.

[0036] Generally, patients with DCIS have a good prognosis, but those younger than 40 years, African American women, and those with ER negPatients with DCIS have a somewhat higher risk of dying from subsequent BC that appears not to be prevented by either surgery or radiation. A second problem is that many younger patients also present with larger areas of HER2-expressing DCIS, including T1a / T1b invasive sites. These patients are typically either treated with mastectomy due to the size of the calcified sites, or with intensive neoadjuvant chemotherapy regimens of carboplatin, taxotere and trastuzumab and pertuzumab (PTCH), or taxol and trastuzumab (TH), with good survival rates but suffering the long-term effects of extensive surgery, radiation, and chemotherapy. In the era of personalized medicine, these patients need more personalized and effective treatments that reduce the probability of subsequent BC mortality while at the same time reducing the overtreatment they receive from chemotherapy, a year of trastuzumab, radiation, and often mastectomy. Patients with metastatic breast cancer (MBC) are in desperate need of novel immunotherapies to reduce mortality, especially in patients who become resistant to targeted therapies.

[0037] Overexpression of HER-2 / neu plays an important role in breast cancer (BC) development, and its expression in ductal carcinoma in situ (DCIS) is associated with the development of invasive BC (IBC). Patients with HER2-positive DCIS and invasive BC progressively lose systemic anti-HER2 Th1 immune responses. Administration of a class II HER2 peptide-pulsed type 1 polarized dendritic cell vaccine (HER2-DC1) partially restored anti-HER2 Th1 immune responses in DCIS, resulting in approximately 30% pathological complete response (pCR). There is an opportunity to improve immune responses and clinical activity in patients with early-stage HER2 BC. Semaphorin 4D (SEMA4D) is a family of soluble and transmembrane proteins that are essential for tissue and organ development and are involved in immune regulation. Overexpression of SEMA4D correlates with poor prognosis and tumor progression in various cancers. In this study, we investigated a murine anti-SEMA4D monoclonal antibody (provided by Vaccinex) in combination with the DC1 vaccine to enhance antitumor immune responses in a preclinical model of HER2-positive TUBO breast cancer.

[0038] In one aspect, disclosed herein is an anti-cancer combination therapy comprising at least one dendritic cell pulsed with an onco-driver (such as human epidermal growth factor receptor HER2) and at least one inhibitor of an immunomodulatory molecule (such as semaphorin (SEMA) 4D (SEMA4D) or VEGF). In certain non-limiting aspects, the immunomodulatory molecule that is inhibited can affect the vasculature of a tumor.

[0039] It is understood and contemplated herein that the disclosed anti-cancer combination therapy can be used to treat, prevent, alleviate, and / or inhibit any disease in which uncontrolled cell proliferation occurs, such as cancer, including primary and distant tumors.A non-limiting list of different types of cancer is as follows: lymphoma (Hodgkin and non-Hodgkin), leukemia, carcinoma, solid tissue carcinoma, squamous cell carcinoma, adenocarcinoma, sarcoma, glioma, high-grade glioma, blastoma, neuroblastoma, plasmacytoma, histiocytoma, melanoma, adenoma, hypoxic tumor, myeloma, AIDS-related lymphoma or sarcoma, metastatic cancer, or cancer in general.

[0040] A representative, but non-limiting list of cancers that can be treated with the disclosed compositions is as follows: lymphoma, B-cell lymphoma, T-cell lymphoma, mycosis fungoides, Hodgkin's disease, myeloid leukemia, bladder cancer, brain cancer, nervous system cancer, head and neck cancer, squamous cell carcinoma of the head and neck, lung cancer such as small cell lung cancer and non-small cell lung cancer, neuroblastoma / glioblastoma, ovarian cancer, skin cancer, liver cancer, melanoma, squamous cell carcinoma of the oral cavity, throat, pharynx, and lung, cervical cancer, breast cancer (including triple-negative breast cancer, metastatic breast cancer (MBC), ductal carcinoma in situ (DCIS), and invasive breast cancer (IBC)), as well as epithelial cancer, renal cancer, genitourinary cancer, lung cancer, esophageal cancer, head and neck cancer, colon cancer, hematopoietic cancer; testicular cancer; colorectal cancer, prostate cancer, or pancreatic cancer. Thus, in one aspect, disclosed herein is a method of treating, preventing, alleviating, and / or inhibiting cancer in a subject (e.g., including breast cancer (including triple-negative breast cancer, metastatic breast cancer (MBC), ductal carcinoma in situ (DCIS), and invasive breast cancer (IBC)), melanoma, colorectal cancer, pancreatic cancer, and prostate cancer, including primary and distant tumors), comprising administering an anti-cancer combination therapy of any of the aforementioned aspects. For example, disclosed herein is a method of treating, preventing, alleviating, and / or inhibiting cancer in a subject, comprising administering to the subject at least one dendritic cell pulsed with an oncodriver (e.g., human epidermal growth factor receptor (HER) HER2, etc.) and at least one inhibitor of an immunomodulatory molecule (e.g., semaphorin (SEMA) 4D (SEMA4D) or VEGF, etc.). In certain non-limiting aspects, the immunomodulatory molecule that is inhibited may affect the vasculature of the tumor.

[0041] In one aspect, it is understood that the disclosed method and anticancer combination therapy comprises the inhibitor of immunomodulatory molecules that have immunomodulatory effect and in certain non-limiting aspects can also affect tumor vasculature.It is understood and contemplated herein that said inhibitor can comprise any small molecule, peptide, protein, antibody (including any functional fragment of antibody or other binding molecule), and / or functional nucleic acid (siRNA, RNA, aptamer) that inhibits the immunomodulatory and / or vascular activity of immunomodulatory molecules.In one aspect, the inhibitor of immunomodulatory molecules comprises SEMA4D inhibitor pepinemab (anti-SEMA4D antibody).

[0042] antibody Antibodies in general The term "antibody" is used broadly herein and includes both polyclonal and monoclonal antibodies. In addition to intact immunoglobulin molecules, fragments or polymers of immunoglobulin molecules, and human or humanized forms of immunoglobulin molecules or fragments thereof, are also included in the term "antibody", so long as they are selected for their ability to interact with immunomodulatory molecules, such as semaphorin (SEMA) 4D (SEMA4D) or VEGF, such that the immunomodulatory activity and / or its effect on the tumor vasculature is inhibited. Antibodies can be tested for their desired activity using the in vitro assays described herein or by similar methods, and then tested for in vivo therapeutic and / or prophylactic activity according to known clinical testing methods. "Native antibodies" are usually heterotetrameric glycoproteins composed of two identical light (L) chains and two identical heavy (H) chains. Typically, each light chain is linked to a heavy chain by one covalent disulfide bond, although the number of disulfide bonds varies among the heavy chains of different immunoglobulin isotypes. Each heavy and light chain also has regularly spaced intrachain disulfide bridges. Each heavy chain has a variable domain (V(H)) at one end followed by several constant domains. Each light chain has a variable domain (V(L)) at one end and a constant domain at the other end; the constant domain of the light chain is aligned with the first constant domain of the heavy chain, and the light chain variable domain is aligned with the variable domain of the heavy chain. Particular amino acid residues are believed to form an interface between the light chain variable domain and the heavy chain variable domain. The light chains of antibodies from any vertebrate species can be assigned to one of two clearly distinct types, called kappa (κ) and lambda (λ), based on the amino acid sequences of their constant domains. Immunoglobulins can be assigned to different classes depending on the amino acid sequences of the constant domains of their heavy chains.There are five major classes of human immunoglobulins: IgA, IgD, IgE, IgG, and IgM, some of which can be further divided into subclasses (isotypes), e.g., IgG-1, IgG-2, IgG-3, and IgG-4; IgA-1 and IgA-2. Those skilled in the art will recognize the equivalent classes for mice. The heavy chain constant domains that correspond to the different classes of immunoglobulins are designated alpha, delta, epsilon, gamma, and mu, respectively.

[0043] The term "variable" is used herein to describe certain portions of the variable domains that differ in sequence among antibodies and that are used in the binding and specificity of each particular antibody to its particular antigen. However, the variability is not evenly distributed throughout the variable domains of antibodies. The variability is concentrated in three segments, called complementarity determining regions (CDRs) or hypervariable regions, in both the light and heavy chain variable domains. The more highly conserved portions of the variable domains are called frameworks (FRs). Natural heavy and light chain variable domains each contain four FR regions that are largely in a β-sheet configuration, connected by three CDRs, which form loops that connect and in some cases form part of the β-sheet structure. The CDRs of each chain are held in close proximity by the FR regions and, together with the CDRs from the other chain, contribute to the formation of the antigen-binding site of antibodies (see Kabat EA et al., "Sequences of Proteins of Immunological Interest," National Institutes of Health, Bethesda, Md. (1987)). The constant domains are not involved directly in binding an antibody to an antigen, but exhibit various effector functions, such as participating in antibody-dependent cellular cytotoxicity.

[0044] In certain antibodies, or antigen-binding fragments, variants, or derivatives thereof disclosed herein (such as, for example, the anti-SEMA4D antibody pepinemab), the heavy chain portion of one polypeptide chain of the multimer is identical to the heavy chain portion on the second polypeptide chain of the multimer. Alternatively, the monomers that comprise the heavy chain portion are not identical. For example, each monomer may comprise a different target binding site, for example forming a bispecific antibody.

[0045] The heavy chain portions of the binding molecules for use in the diagnostic and treatment methods disclosed herein can be derived from different immunoglobulin molecules. For example, the heavy chain portion of the polypeptide can be derived from a C IgG1 molecule. H1 In another example, a heavy chain portion may comprise a hinge region derived, in part, from an IgG1 molecule and, in part, from an IgG3 molecule. In another example, a heavy chain portion may comprise a chimeric hinge derived, in part, from an IgG1 molecule and, in part, from an IgG4 molecule.

[0046] As used herein, a "light chain portion" comprises an amino acid sequence derived from an immunoglobulin light chain, such as a kappa or lambda light chain. Preferably, the light chain portion comprises at least one of a VL domain or a CL domain.

[0047] The anti-SEMA4D antibodies disclosed herein, or antigen-binding fragments, variants, or derivatives thereof, may be described or specified in terms of the epitope or portion of the antigen they recognize or specifically bind, such as the target polypeptide (e.g., SEMA4D) disclosed herein. The portion of the target polypeptide that specifically interacts with the antigen-binding domain of the antibody is an "epitope" or "antigenic determinant." A target polypeptide may contain a single epitope, but typically contains at least two epitopes, and may contain any number of epitopes depending on the size, conformation, and type of antigen. Furthermore, it is noted that an "epitope" on a target polypeptide may be or may include non-polypeptide elements, for example, an epitope may include a sugar side chain.

[0048] The minimum size of a peptide or polypeptide epitope for an antibody is believed to be about 4-5 amino acids. A peptide or polypeptide epitope preferably contains at least 7 amino acids, more preferably at least 9 amino acids, and most preferably at least about 15 to about 30 amino acids. Because the CDRs may recognize an antigenic peptide or polypeptide in its tertiary form, the amino acids that make up the epitope need not be adjacent, and in some cases may not even be on the same peptide chain. A peptide or polypeptide epitope recognized by an anti-SEMA4D antibody may contain a sequence of at least 4, at least 5, at least 6, at least 7, more preferably at least 8, at least 9, at least 10, at least 15, at least 20, at least 25, or about 15 to about 30 consecutive or non-consecutive amino acids of SEMA4D.

[0049] "Specifically bind" generally means that an antibody binds to an epitope through its antigen-binding domain, and that the binding requires some complementarity between the antigen-binding domain and the epitope. According to this definition, an antibody is said to "specifically bind" to an epitope if it binds to that epitope through its antigen-binding domain more readily than it binds to a random, unrelated epitope. The term "specificity" is used herein to describe the relative affinity with which a particular antibody binds to a particular epitope. For example, antibody "A" can be considered to have a higher specificity for a given epitope than antibody "B", or antibody "A" can be said to bind epitope "C" with a higher specificity than it has for related epitope "D".

[0050] "Preferentially binds" means that an antibody specifically binds to an epitope more readily than it binds to a related, similar, homologous, or analogous epitope. Thus, an antibody that "preferentially binds" to a given epitope is more likely to bind to that epitope than to a related epitope, even if such an antibody may cross-react with the related epitope.

[0051] The term "monoclonal antibody" as used herein refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e., the individual antibodies in the population are identical except for possible naturally occurring mutations that may exist in a small proportion of antibody molecules. Monoclonal antibodies herein specifically include "chimeric" antibodies in which a portion of the heavy and / or light chain is identical or homologous to corresponding sequences in antibodies from a particular species or belonging to a particular antibody class or subclass, and the remainder of the chain is identical or homologous to corresponding sequences in antibodies from another species or belonging to another antibody class or subclass, as well as fragments of such antibodies so long as they exhibit the desired antagonistic activity.

[0052] The disclosed monoclonal antibodies can be produced using any procedure that produces monoclonal antibodies. For example, the disclosed monoclonal antibodies can be prepared using the hybridoma method, such as the method described by Kohler and Milstein, Nature, 256:495 (1975). In the hybridoma method, typically, a mouse or other suitable host animal is immunized with an immunizing agent to induce lymphocytes that produce or are capable of producing antibodies that specifically bind to the immunizing agent. Alternatively, lymphocytes can be immunized in vitro.

[0053] Monoclonal antibodies may be produced by recombinant DNA methods. DNA encoding the disclosed monoclonal antibodies can be easily isolated and sequenced using conventional procedures (e.g., by using oligonucleotide probes capable of specifically binding to genes encoding the heavy and light chains of mouse antibodies). Libraries of antibodies or active antibody fragments can also be produced and screened using phage display techniques, such as those described in U.S. Patent No. 5,804,440 to Burton et al. and U.S. Patent No. 6,096,441 to Barbas et al.

[0054] In vitro methods are also suitable for preparing monovalent antibodies. Digestion of antibodies to generate fragments thereof, particularly Fab fragments, can be accomplished using routine techniques known in the art. For example, digestion can be performed using papain. Examples of papain digestion are described in WO 94 / 29348 published on December 22, 1994 and U.S. Pat. No. 4,342,566. Papain digestion of antibodies typically produces two identical antigen-binding fragments, called Fab fragments, each of which has a single antigen-binding site, and a remaining Fc fragment. Pepsin treatment produces a fragment that has two antigen-binding sites and can still crosslink with antigen.

[0055] As used herein, the term "antibody or fragment thereof" refers to F(ab')2, Fab', Fab, Fv, scFv, disulfide-linked Fv (sdFv), VFv, F(ab')2 ... H or V L The term "antibody or fragment thereof" encompasses fragments such as fragments that include one or both of the domains. Thus, fragments of antibodies that retain the ability to bind to a specific antigen are provided. For example, fragments of antibodies that retain immunomodulatory molecule (e.g., semaphorin (SEMA) 4D (SEMA4D) or VEGF) binding activity are included within the meaning of the term "antibody or fragment thereof". Such antibodies and fragments can be produced by techniques known in the art and screened for specificity and activity according to the methods described in the Examples, as well as in general methods for generating antibodies and screening antibodies for specificity and activity (see Harlow and Lane. Antibodies, A Laboratory Manual. Cold Spring Harbor Publications, New York, (1988)).

[0056] Antibody fragments and conjugates of antigen-binding proteins (single-chain antibodies) are also included within the meaning of "antibody or fragment thereof."

[0057] The fragments may also contain insertions, deletions, substitutions, or other selected modifications of specific regions or specific amino acid residues, whether or not linked to other sequences, so long as the activity of the antibody or antibody fragment is not significantly altered or impaired compared to the unmodified antibody or antibody fragment. These modifications may provide some additional properties, such as removing / adding amino acids capable of disulfide bonding, extending its biological lifespan, altering its secretion properties, etc. In any case, the antibody or antibody fragment must have a biologically active property, such as specific binding to its cognate antigen. Functional or active regions of the antibody or antibody fragment can be identified by mutagenesis of specific regions of the protein, followed by expression and testing of the expressed polypeptide. Such methods are readily apparent to those skilled in the art and may include site-directed mutagenesis of the nucleic acid encoding the antibody or antibody fragment (Zoller, MJ Curr. Opin. Biotechnol. 3:348-354, 1992).

[0058] As used herein, the term "heavy chain portion" includes an amino acid sequence derived from an immunoglobulin heavy chain. A polypeptide comprising a heavy chain portion includes at least one of a CH1 domain, a hinge (e.g., upper, middle, and / or lower hinge region) domain, a CH2 domain, a CH3 domain, or a variant or fragment thereof.

[0059] As used herein, the term "antibody" or "antibodies" can also refer to human and / or humanized antibodies. Many non-human antibodies (e.g., those derived from mouse, rat, or rabbit) are naturally antigenic in humans and can therefore cause undesirable immune responses when administered to humans. Thus, the use of human or humanized antibodies in the present methods helps to reduce the likelihood that antibodies administered to humans will cause undesirable immune responses.

[0060] Human antibodies The disclosed human antibodies can be prepared using any technique. The disclosed human antibodies can also be obtained from transgenic animals. For example, transgenic mutant mice that can produce a full repertoire of human antibodies in response to immunization have been described (see, for example, Jakobovits et al., Proc. Natl. Acad. Sci. USA, 90:2551-255 (1993); Jakobovits et al., Nature, 362:255-258 (1993); Bruggermann et al., Year in Immunol., 7:33 (1993)). Specifically, homozygous deletion of the antibody heavy chain joining region (J(H)) gene in these chimeric germline mutant mice completely inhibits endogenous antibody production, and successful introduction of the human germline antibody gene array into such germline mutant mice results in the production of human antibodies upon antigen challenge. Antibodies with the desired activity are selected using the Env-CD4-co-receptor complexes as described herein.

[0061] Humanized antibodies Antibody humanization techniques generally involve the use of recombinant DNA technology to manipulate the DNA sequence encoding one or more polypeptide chains of an antibody molecule. Thus, a humanized form of a non-human antibody (or a fragment thereof) is a chimeric antibody or antibody chain (or a fragment thereof, such as sFv, Fv, Fab, Fab', F(ab')2, or other antigen-binding portion of an antibody) that contains a portion of the antigen-binding site from a non-human (donor) antibody incorporated into the framework of a human (recipient) antibody.

[0062] To generate a humanized antibody, residues from one or more complementarity determining regions (CDRs) of a recipient (human) antibody molecule are replaced with residues from one or more CDRs of a donor (non-human) antibody molecule that are known to have the desired antigen-binding properties (e.g., a certain level of specificity and affinity for the target antigen). Optionally, Fv framework (FR) residues of the human antibody are replaced with corresponding non-human residues. Humanized antibodies may also contain residues that are found neither in the recipient antibody nor in the imported CDR or framework sequences. Generally, humanized antibodies have one or more amino acid residues introduced from a source that is non-human. In practice, humanized antibodies are typically human antibodies in which some CDR residues and possibly some FR residues are replaced by residues from analogous sites in rodent antibodies. A humanized antibody generally comprises at least a portion of an antibody constant region (Fc), typically that of a human antibody (Jones et al., Nature, 321:522-525 (1986); Reichmann et al., Nature, 332:323-327 (1988); and Presta, Curr. Opin. Struct. Biol., 2:593-596 (1992)).

[0063] The method of humanizing non-human antibodies is well known in the art.For example, humanized antibodies can be produced by replacing the corresponding sequences of human antibodies with rodent CDRs or CDR sequences according to the method of Winter et al. (Jones et al., Nature, 321:522-525 (1986); Riechmann et al., Nature, 332:323-327 (1988); Verhoeyen et al., Science, 239:1534-1536 (1988)). Methods that can be used to generate humanized antibodies are also described in U.S. Pat. No. 4,816,567 (Cabilly et al.), U.S. Pat. No. 5,565,332 (Hoogenboom et al.), U.S. Pat. No. 5,721,367 (Kay et al.), U.S. Pat. No. 5,837,243 (Deo et al.), U.S. Pat. No. 5,939,598 (Kucherlapati et al.), U.S. Pat. No. 6,130,364 (Jakobovits et al.), and U.S. Pat. No. 6,180,377 (Morgan et al.).

[0064] Anti-SEMA4D antibody In one aspect, the inhibitor of an immune-modulating molecule may be the SEMA4D inhibitor pepinemab (anti-SEMA4D antibody), as described in US8496938, US8816058, US9605055, and US9676840, patents which are incorporated herein by reference for their teachings of anti-SEMA4D (anti-DC100) antibodies. Anti-SEMA4D monoclonal antibodies have been developed to neutralize SEMA4D, including MAb 67, MAb 2503, and MAb 76.

[0065] Antibodies that bind to SEMA4D have been described in the art, see, e.g., U.S. Patent Application Publication No. 2008 / 0219971 A1, International Patent Application WO 93 / 14125, and Herold et al., Int. Immunol. 7(1): 1-8 (1995), each of which is incorporated herein by reference in its entirety.

[0066] Anti-SEMA4D antibodies, or antigen-binding fragments, variants, or derivatives thereof, can include, for example, MAb 2503, MAb 67, or MAb 76. In certain embodiments, the anti-SEMA4D antibodies bind to human, mouse, or both human and mouse SEMA4D. In other embodiments, the anti-SEMA4D antibodies block SEMA4D from binding to its receptors, such as plexin-B1 or plexin-B2.

[0067] It is understood and contemplated herein that the disclosed anti-cancer combination therapies, and methods of treating, inhibiting, ameliorating, and / or preventing cancer using the anti-cancer combination therapies, can include two or more immune modulatory molecule inhibitors and two or more populations of pulsed dendritic cells, each population of pulsed dendritic cells pulsed with the same or a different onco-driver.

[0068] The term "subject" refers to any individual that is the target of administration or treatment. The subject may be a vertebrate, for example a mammal. In one aspect, the subject may be a human, a non-human primate, a cow, a horse, a pig, a dog, or a cat. The subject may also be a guinea pig, a rat, a hamster, a rabbit, a mouse, or a mole. Thus, the subject may be a human or an animal patient. The term "patient" refers to a subject that is receiving treatment from a clinician, for example a physician.

[0069] The term "therapeutically effective" refers to the amount of the composition used being sufficient to ameliorate one or more causes or symptoms of a disease or disorder. Such amelioration requires only a reduction or alteration, not necessarily elimination.

[0070] The term "treatment" refers to the medical management of a patient intended to cure, ameliorate, stabilize, or prevent a disease, pathological condition, or disorder. The term includes active treatment, i.e., treatment specifically directed to ameliorate a disease, pathological condition, or disorder, and also includes causal treatment, i.e., treatment directed to remove the cause of the associated disease, pathological condition, or disorder. In addition, the term includes palliative treatment, i.e., treatment designed to relieve symptoms rather than cure the disease, pathological condition, or disorder; preventive treatment, i.e., treatment directed to minimize or partially or completely inhibit the occurrence of the associated disease, pathological condition, or disorder; and supportive treatment, i.e., treatment used to supplement another specific therapy directed to ameliorate the associated disease, pathological condition, or disorder.

[0071] It is understood and contemplated herein that in one aspect, the pulsed dendritic cells can be activated prior to administration and prior to being pulsed with an onco-driver. Activation of dendritic cells (DC1) can be achieved by contacting the cells with IFN-γ, TNFα, CD40, IL21, and / or IL-12. It is further understood that in one aspect, a subject's own dendritic cells can be harvested, pulsed ex vivo, and returned to the subject for use in the disclosed anti-cancer combination therapies to treat, prevent, reduce, and / or inhibit cancer.

[0072] It is understood and contemplated herein that the disclosed anti-cancer combination therapy may be administered via any route as determined by the attending physician as appropriate. "Administering" to a subject includes any route of introducing or delivering an agent locally and / or systemically to a subject. Administration may be performed by any suitable route, including oral, topical, intravenous, subcutaneous, transcutaneous, transdermal, intramuscular, intra-articular, parenteral, intra-arteriolar, intradermal, intraventricular, intracranial, intraperitoneal, intralesional, intranasal, rectal, intravaginal, by inhalation, via an implanted reservoir, parenteral (e.g., subcutaneous, intravenous, intramuscular, intra-articular, intrasynovial, intratumoral, intrasternal, intrathecal, intraperitoneal, intrahepatic, intralesional, and intracranial injection or infusion techniques), and the like. As used herein, "concurrent administration," "co-administration," "simultaneous administration," or "administered simultaneously" means that the compounds are administered at the same time or essentially immediately after each other. In the latter case, the two compounds are administered close enough in time that the results observed are indistinguishable from the results achieved if the compounds were administered at the same time. "Systemic administration" refers to the introduction or delivery of an agent to a subject via a route that introduces or delivers the agent to a broad area of ​​the subject's body (e.g., more than 50% of the body), for example, through an entrance into the circulatory or lymphatic system. In contrast, "local administration" refers to the introduction or delivery of an agent to a subject via a route that introduces or delivers the agent to an area at or immediately adjacent to the point of administration, and does not introduce a therapeutically significant amount of the agent into the whole body. For example, a locally administered agent is readily detectable in the local vicinity of the point of administration, but is undetectable or detectable in negligible amounts in distal parts of the subject's body. Administration includes self-administration and administration by another. In one aspect, disclosed herein is an anti-cancer combination therapy method for treating, preventing, ameliorating, and / or inhibiting cancer of any of the aforementioned aspects, wherein at least one immune modulatory molecule inhibitor is administered systemically and / or onco-driver pulsed dendritic cells are administered intratumorally.

[0073] While a single administration of the components of the disclosed anti-cancer combination therapy (i.e., pulsed dendritic cells and / or immune modulatory molecule inhibitors) would be ideal, it is understood and contemplated herein that not all patients will respond in the same manner. Thus, in one aspect, disclosed herein is an anti-cancer combination therapy method for treating, preventing, ameliorating, and / or inhibiting cancer, wherein at least one pulsed dendritic cell is administered at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, or 24 times per day, or at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, or 14 times per week for at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, or 14 days, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 weeks. Also disclosed herein is an anti-cancer combination therapy method for treating, preventing, alleviating and / or inhibiting cancer of any of the above aspects, wherein at least one immunomodulatory molecule inhibitor is administered at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 days, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 or 24 times per day, or at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13 or 14 times per week for at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13 or 14 days, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 weeks.It is further understood and contemplated herein that the order and duration of administration of components can vary depending on the subject being treated.In one aspect, the pulsed dendritic cells are administered at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 18, 24, 30, 36 hours, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 21, 28, 30, 31, 45 days, 2, 3, 4, 5, or 6 months prior to administration of at least one immune modulating molecule inhibitor; administered simultaneously with at least one immune modulating molecule inhibitor; or administered at least one Disclosed herein is an anti-cancer combination therapy method for treating, preventing, ameliorating, and / or inhibiting cancer, wherein an immune modulatory molecule inhibitor of is administered at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 18, 24, 30, 36 hours, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 21, 28, 30, 31, 45 days, 2, 3, 4, 5, or 6 months prior to administration of pulsed dendritic cells.

[0074] As mentioned above, it is intended herein that the disclosed methods of treating, inhibiting, alleviating, and / or preventing cancer can be augmented with any therapeutic treatment of cancer, including but not limited to surgical treatment, radiation treatment, and / or pharmaceutical treatment of cancer.As used herein, "surgical treatment" refers to tumor resection of tumor by any means known in the art. Similarly, "pharmaceutical treatment" refers to the administration of any anti-cancer agent known in the art, including, but not limited to, abemaciclib, abiraterone acetate, Abitrexate (methotrexate), Abraxane (paclitaxel-albumin-stabilized nanoparticle formulation), ABVD, ABVE, ABVE-PC, AC, AC-T, Adcetris (brentuximab vedotin), ADE, adotrastuzumab emtansine, Adriamycin (doxorubicin hydrochloride), afatinib dimaleate, Afinitor (everolimus), Akynzeo (netupitant-palonosetron hydrochloride), Aldara (imiquimod), aldesleukin, Alecensa (altegravir), , Alectinib, Alemtuzumab, Alimta (Pemetrexed Disodium), Aliqopa (Copanlisib Hydrochloride), Alkeran Injection (Melphalan Hydrochloride), Alkeran Tablets (Melphalan), Aloxi (Palonosetron Hydrochloride), Alunbrig (Brigatinib), Ambochlorin (Chlorambucil), Ambochlorin (Chlorambucil), Amifostine, Aminolevulinic Acid, Anastrozole, Aprepitant, Aredia (Pamidronate Disodium), Arimedex (Anastrozole), Aromasin (Exemestane), Arranon (Nelarabine), Arsenic Trioxide, Arzerra (Ofatumumab), Blackleg Disease (Erwinia chrysanthemi) Asparaginase, Atezolizumab, Avastin (bevacizumab), Avelumab, Axitinib, Azacitidine, Bavencio (avelumab), BEACOPP, Becenum (carmustine), Beleodaq (belinostat), belinostat, bendamustine hydrochloride, BEP, Besponsa (inotuzumab ozogamicin), Bevacizumab, Bexarotene,Bexxar (tositumomab and iodine I 131 tositumomab), bicalutamide, BiCNU (carmustine), bleomycin, blinatumomab, Blincyto (blinatumomab), bortezomib, Bosulif (bosutinib), bosutinib, brentuximab vedotin, brigatinib, BuMel, busulfan, Busulfex (busulfan), cabazitaxel, Cabometyx (cabozantinib-S-malate), cabozantinib-S-malate, CAF, Campath (alemtuzumab), Camptosar (irinotecan hydrochloride), Capecitabine Tabine, CAPOX, Carac (fluorouracil-topical), carboplatin, carboplatin-taxol, carfilzomib, Carmubris (carmustine), carmustine, carmustine implant, Casodex (bicalutamide), CEM, ceritinib, Cerubidine (daunorubicin hydrochloride), Cervarix (recombinant HPV bivalent vaccine), cetuximab, CEV, chlorambucil, chlorambucil-prednisone, CHOP, cisplatin, cladribine, Clafen (cyclophosphamide) ), clofarabine, Clofarex (clofarabine), Clolar (clofarabine), CMF, cobimetinib, Cometriq (cabozantinib-S-malate), copanlisib hydrochloride, COPDAC, COPP, COPP-ABV, Cosmegen (dactinomycin), Cotellic (cobimetinib), crizotinib, CVP, cyclophosphamide, Cyfos (ifosfamide), Cyramza (ramucirumab), cytarabine, cytarabine liposomal, Cytosar-U (cytarabine), Cytoxa n (cyclophosphamide), dabrafenib, dacarbazine, Dacogen (decitabine), dactinomycin, daratumumab, Darzalex (daratumumab), dasatinib, daunorubicin hydrochloride, daunorubicin hydrochloride and cytarabine liposome, decitabine, defibrotide sodium, Defitelio (defibrotide sodium), degarelix, denileukin diftitox, denosumab, DepoCyt (cytarabine liposome), dexamethasone, dexrazoxane hydrochloride, dinutuximab, docetaxel,Doxil (doxorubicin hydrochloride liposomal), doxorubicin hydrochloride, doxorubicin hydrochloride liposomal, Dox-SL (doxorubicin hydrochloride liposomal), DTIC-Dome (dacarbazine), durvalumab, Efudex (fluorouracil-topical), Elitek (rasburicase), Ellence (epirubicin hydrochloride), elotuzumab, Eloxatin (oxaliplatin), eltrombopag olamine, Emend (aprepitant), Empliciti (elotuzumab), enasidenib mesylate, enzalutamide, epirubicin hydrochloride, EPOCH, Erbitux (cetuximab), eribulin mesylate, Erivedge (vismodegib), erlotinib hydrochloride, Erwinaze (blackleg asparaginase), Ethyol (a Mifostine), Etopophos (etoposide phosphate), etoposide, etoposide phosphate, Evacet (doxorubicin hydrochloride liposomal), everolimus, Evista, (raloxifene hydrochloride), Evomela (melphalan hydrochloride), exemestane, 5-FU (fluorouracil injection), 5-FU (fluorouracil - topical), Fareston (toremifene), Farydak (panobinostat), Faslodex (fulvestrant), FEC, Femara (letrozole), Filgrastim, Fludara (fludarabine phosphate), Fludarabine phosphate, Fluoroplex (fluorouracil - topical), fluorouracil injection, fluorouracil - topical, flutamide, Folex (methotrexate), Folex PFS (methotrexate), FOLFIRI, FOLFIRI-bevacizumab, FOLFIRI-cetuximab, FOLFIRINOX, FOLFOX, Folotyn (pralatrexate), FU-LV, fulvestrant, Gardasil (recombinant HPV quadrivalent vaccine), Gardasil 9 (recombinant HPV nonavalent vaccine), Gazyva (obinutuzumab), gefitinib, gemcitabine hydrochloride, gemcitabine-cisplatin, gemcitabine-oxaliplatin, gemtuzumab ozogamicin, Gemzar (gemcitabine hydrochloride), Gilotrif (afatinib dimaleate), Gleevec (imatinib mesylate),Gliadel (carmustine implant), Gliadel wafer (carmustine implant), glucarpidase, goserelin acetate, Halaven (eribulin mesylate), Hemangeol (propranolol hydrochloride), Herceptin (trastuzumab), recombinant HPV bivalent vaccine, recombinant HPV nonavalent vaccine, recombinant HPV quadrivalent vaccine, Hycamtin (topotecan hydrochloride), Hydrea (hydroxyurea), hydroxyurea, Hyper-CVAD, Ibrance (palbociclib), ibritumomab tiuxetan, ibrutinib, ICE, Iclusig (ponatinib hydrochloride), Idamyci n(idarubicin hydrochloride), idarubicin hydrochloride, idelalisib, Idhifa(enasidenib mesylate), Ifex(ifosfamide), ifosfamide, Ifosfamidum(ifosfamide), IL-2(aldesleukin), imatinib mesylate, Imbruvica(ibrutinib), Imfinzi(durvalumab), imiquimod, Imlygic(talimogene laherparepvec), Inlyta(axitinib), inotuzumab ozogamicin, recombinant interferon alpha-2b, interleukin-2(aldesleukin), Intron A(recombinant interferon alpha-2b), iodine I 131 Tositumomab and tositumomab, ipilimumab, Iressa (gefitinib), irinotecan hydrochloride, irinotecan hydrochloride liposomal, Istodax (romidepsin), ixabepilone, ixazomib citrate, Ixempra (ixabepilone), Jakafi (ruxolitinib phosphate), JEB, Jevtana (cabazitaxel), Kadcyla (adotrastuzumab emtansine), Keoxifene (raloxifene hydrochloride), Kepivance (palifermin), Keytruda (pembrolizumab), Kisqali (ribociclib), Kymriah (tisagenlecleucel), Kyprolis (carfilzomib), lanreotide acetate, lapatinib ditosylate, Lartruvo (olaratumab), lenalidomide, lenvatinib mesylate, Lenvima (lenvatinib mesylate), letrozole, leucovorin calcium, Leukeran (chlorambucil),Leuprolide Acetate, Leustatin (Cladribine), Levulan (Aminolevulinic Acid), Linfolizin (Chlorambucil), LipoDox (Doxorubicin Hydrochloride Liposomal), Lomustine, Lonsurf (Tifluridine-Tipiracil Hydrochloride), Lupron (Leuprolide Acetate), Lupron Depot (Leuprolide Acetate), Lupron Depot-Ped (Leuprolide Acetate), Lynparza (Olaparib), Marqibo (Vincristine Sulfate Liposomal), Matulane (Procarbazine Hydrochloride), Mechlorethamine Hydrochloride, Megestrol Acetate, Mekinist (Trametinib), Melphalan, Melphalan Hydrochloride, Mercaptopurine, Mesna, Mesnex (Mesna), Methazolastone (Temozolomide), Methotrexate, Methotrexate LP F (methotrexate), methylnaltrexone bromide, Mexate (methotrexate), Mexate-AQ (methotrexate), midostaurin, mitomycin C, mitoxantrone hydrochloride, Mitozytrex (mitomycin C), MOPP, Mozobil (plelixafor), Mustargen (mechlorethamine hydrochloride), Mutamycin (mitomycin C), Myleran (busulfan), Mylosar (azacitidine) gin), Mylotarg (gemtuzumab ozogamicin), nanoparticle paclitaxel (paclitaxel-albumin-stabilized nanoparticle formulation), Navelbine (vinorelbine tartrate), necitumumab, nelarabine, Neosar (cyclophosphamide), neratinib maleate, Nerlynx (neratinib maleate), netupitant-palonosetron hydrochloride, Neulasta (pegfilgrastim), Neupogen (filgrastim ), Nexavar (sorafenib tosylate), Nilandron (nilutamide), nilotinib, nilutamide, Ninlaro (ixazomib citrate), niraparibut tosylate monohydrate, nivolumab, Nolvadex (tamoxifen citrate), Nplate (romiplostim), obinutuzumab, Odomzo (sonidegib), OEPA, ofatumumab, OFF, olaparib, olaratumab, omacetaxine mepesuxinate,Oncaspar (pegaspargase), ondansetron hydrochloride, Onivyde (irinotecan hydrochloride liposomal), Ontak (denileukin diftitox), Opdivo (nivolumab), OPPA, osimertinib, oxaliplatin, paclitaxel, paclitaxel-albumin stabilized nanoparticle formulation, PAD, palbociclib, palifermin, palonosetron hydrochloride, palonosetron hydrochloride-netupitant, pamidronate disodium, panitumumab, panobinostat, Paraplat (carboplatin), Paraplatin (carboplatin), pazopanib hydrochloride, PCV, PEB, pegaspargase, pegfilgrastim, peginterferon alfa 2b, PEG-Intron (peginterferon alfa-2b), pembrolizumab, Pemetrexed disodium, Perjeta (pertuzumab), pertuzumab, Platinol (cisplatin), Platinol-AQ (cisplatin), plerixafor, pomalidomide, Pomalyst (pomalidomide), ponatinib hydrochloride, Portrazza (necitumumab), pralatrexate, prednisone, procarbazine hydrochloride, Proleukin (aldesleukin), Prolia (denosumab), Promacta (eltrombopagulamine), propranolol hydrochloride, Provenge (sipuleucel-T), Purinethol (mercaptopurine), Purixan (mercaptopurine), radium-223 chloride, raloxifene hydrochloride, ramucirumab, rasburicase, R-CHOP, R-CVP, recombinant human papillomavirus (HPV) Bivalent Vaccine, Recombinant Human Papillomavirus (HPV) Nonavalent Vaccine, Recombinant Human Papillomavirus (HPV) Quadrivalent Vaccine, Recombinant Interferon Alpha-2b, Regorafenib, Relistor (Methylnaltrexone Bromide), R-EPOCH, Revlimid (Lenalidomide), Rheumatrex (Methotrexate), Ribociclib, R-ICE, Rituxan (Rituximab), Rituxan Hycela (Rituximab-Human Hyaluronidase), Rituximab, Rituximab-Human Hyaluronidase, Rolapitant Hydrochloride, Romidepsin, Romiplostim,Rubidomycin (daunorubicin hydrochloride), Rubraca (ru, Caparib camsylate), Rucaparib camsylate, Ruxolitinib phosphate, Rydapt (midostaurin), Sclerosol Intrapleural Aerosol (talc), Siltuximab, Sipuleucel-T, Somatuline Depot (lanreotide acetate), Sonidegib, Sorafenib tosylate, Sprycel (dasatinib), STANFORD V, Sterile Talc Powder (Talc), Steritalc (Talc), Stivarga (Regorafenib), Sunitinib Malate, Sutent (Sunitinib Malate), Sylatron (Peginterferon alfa-2b), Sylvant (Siltuximab), Synribo (Omacetaxine Mepesuccinate), Tabloid (Thioguanine), TAC, Tafinlar (Dabrafenib), Tagrisso (Osimertinib), Talc, Talimogene Laherparepvec, Tamoxifen Citrate, Tarabine PFS (cytarabine), Tarceva (erlotinib hydrochloride), Targretin (bexarotene), Tasigna (nilotinib), Taxol (paclitaxel), Taxotere (docetaxel), Tecentriq (atezolizumab), Temodar (temozolomide), temozolomide, temsirolimus, thalidomide, Thalomid (thalidomide), thioguanine, thiotepa, tisagenlecleucel, Tolak (fluorouracil-topical), topotecan hydrochloride, toremifene, Torisel (temsirolimus), tositumomab and iodine I131 Tositumomab, Totect (dexrazoxane hydrochloride), TPF, trabectedin, trametinib, trastuzumab, Treanda (bendamustine hydrochloride), trifluridine-tipiracil hydrochloride, Trisenox (arsenic trioxide), Tykerb (lapatinib ditosylate), Unituxin (dinutuximab), uridine triacetate, VAC, vandetanib, VAMP, Varubi (Rorapitanib) Vectibix (panitumumab), VeIP, Velban (vinblastine sulfate), Velcade (bortezomib), Velsar (vinblastine sulfate), vemurafenib, Venclexta (venetoclax), venetoclax, Verzenio (abemaciclib), Viadur (leuprolide acetate), Vidaza (azacitidine), vinblastine sulfate, VincasarPFS (vincristine sulfate), vincristine sulfate, vincristine sulfate liposomal, vinorelbine tartrate, VIP, vismodegib, Vistogard (uridine triacetate), Voraxaze (glucarpidase), vorinostat, Votrient (pazopanib hydrochloride), Vyxeos (daunorubicin hydrochloride and cytarabine liposomal), Wellcovorin (leucovorin calcium), Xalkori (crizotinib), Xeloda (capecitabine), XELIRI, XELOX, Xgeva (denosumab), Xofigo (radium-223 chloride), Xtandi (enzalutamide), Yervoy (ipilimumab) ), Yondelis (trabectedin), Zaltrap (Ziv-aflibercept), Zarxio (filgrastim), Zejula (niraparibut tosylate monohydrate), Zelboraf (vemurafenib), Zevalin (ibritumomab tiuxetan), Zinecard (dexrazoxane hydrochloride), Ziv-aflibercept, Zofran (ondansetron hydrochloride), Zoladex (goserelin acetate), zoledronic acid, Zolinza (vorinostat), Zometa (zoledronic acid), Zydelig (idelalisib), Zykadia (ceritinib), and / or Zytiga (abiraterone acetate). Chemotherapeutic agents that are PD1 / PDL1 blocking inhibitors (such as, for example, lambrolizumab, nivolumab, pembrolizumab, pidilizumab, BMS-936559, atezolizumab, durvalumab, or avelumab) are also contemplated herein.

[0075] Pharmaceutical Carriers / Pharmaceutical Product Delivery As mentioned above, the composition can also be administered in vivo in a pharmaceutically acceptable carrier. "Pharmaceutically acceptable" means that the substance is not biologically or otherwise undesirable, i.e., the substance can be administered to a subject together with a nucleic acid or vector without causing any undesirable biological effects or interacting in a harmful manner with any of the other components of the pharmaceutical composition in which it is contained.As is well known to those skilled in the art, the carrier is naturally selected to minimize any degradation of the active ingredient and to minimize any adverse side effects in the subject.

[0076] The compositions can be administered orally, parenterally (e.g., intravenously), by intramuscular injection, by intraperitoneal injection, transdermally, extracorporeally, topically, etc., including administration by local intranasal administration or inhalation. As used herein, "local intranasal administration" refers to delivery of the composition to the nose and nasal cavity via one or both nostrils, and can include delivery by spray or droplet mechanism, or via aerosolization of the nucleic acid or vector. Administration of the composition by inhalation can be via the nose or mouth by delivery by spray or droplet mechanism. Delivery can also be directly to any area of ​​the respiratory system (e.g., lungs) via intubation. The exact amount of the composition required will vary from subject to subject, depending on the species, age, weight, and general condition of the subject, the severity of the allergic disorder being treated, the particular nucleic acid or vector used, its mode of administration, etc. Thus, it is not possible to specify the exact amount of every composition. However, appropriate amounts can be determined by one of skill in the art using only routine experimentation in light of the teachings herein.

[0077] Parenteral administration of compositions, when used, generally features injection.Injection can be prepared in conventional form, either as liquid solution or suspension, solid form suitable for solution or suspension in liquid before injection, or emulsion.More recently modified parenteral administration approach involves the use of sustained release system or sustained release system so that constant dosage is maintained.See, for example, U.S. Patent No. 3,610,795, which is incorporated herein by reference.

[0078] The agents may be in solution, suspension (e.g., incorporated into microparticles, liposomes, or intracellularly), and may be targeted to specific cell types via antibodies, receptors, or receptor ligands. The following references are examples of the use of this technology to target specific proteins to tumor tissue (Senter, et al., Bioconjugate Chem., 2:447-451, (1991); Bagshawe, KD, Br. J. Cancer, 60:275-281, (1989); Bagshawe, et al., Br. J. Cancer, 58:700-703, (1988); Senter, et al., Bioconjugate Chem., 4:3-9, (1993); Battelli, et al., Cancer Immunol. Immunother., 35:421-425, (1992); Pietersz and McKenzie, Immunolog. Reviews, 129:57-80, (1992); and Roffler, et al., Biochem. Pharmacol, 42:2062-2065, (1991)). Vehicles such as "stealth" and other antibody-bound liposomes (including lipid-mediated drug targeting to colon cancer), receptor-mediated targeting of DNA with cell-specific ligands, lymphocyte-tropic tumor targeting, and highly specific therapeutic retroviral targeting of mouse glioma cells in vivo. The following references are examples of the use of this technology to target specific proteins to tumor tissue (Hughes et al., Cancer Research, 49:6214-6220, (1989); and Litzinger and Huang, Biochimica et Biophysica Acta, 1104:179-187, (1992)). In general, receptors are involved in pathways of endocytosis, either constitutively or ligand-induced.These receptors cluster in clathrin-coated pits, enter the cell via clathrin-coated vesicles, and pass through acidified endosomes where the receptors are sorted and then either recycled to the cell surface, stored intracellularly, or degraded in lysosomes. Internalization pathways serve a variety of functions, including uptake of nutrients, removal of activated proteins, clearance of macromolecules, opportunistic entry of viruses and toxins, dissociation and degradation of ligands, and regulation of receptor levels. Many receptors follow more than one intracellular pathway, depending on cell type, receptor concentration, type of ligand, valency of ligand, and concentration of ligand. The molecular and cellular mechanisms of receptor-mediated endocytosis have been reviewed (Brown and Greene, DNA and Cell Biology 10:6, 399-409 (1991)).

[0079] Pharmaceutically acceptable carriers The compositions containing the antibodies can be used therapeutically in combination with a pharma- ceutically acceptable carrier.

[0080] Suitable carriers and their formulations are described in Remington: The Science and Practice of Pharmacy (19th ed.) ed. AR Gennaro, Mack Publishing Company, Easton, PA 1995. Typically, an appropriate amount of a pharma- ceutically acceptable salt is used in the formulation to render the formulation isotonic. Examples of pharma- ceutically acceptable carriers include, but are not limited to, saline, Ringer's solution, and dextrose solution. The pH of the solution is preferably about 5 to about 8, more preferably about 7 to about 7.5. Further carriers include sustained release preparations, such as semipermeable matrices of solid hydrophobic polymers containing an antibody, the matrices being in the form of shaped products, e.g., films, liposomes, or microparticles. It will be apparent to one skilled in the art that certain carriers may be more preferable depending, for example, on the route of administration and concentration of the composition being administered.

[0081] Pharmaceutical carriers are known to those skilled in the art.These are most typically standard carriers for administering drugs to humans, including solutions such as sterile water, saline, and buffer solutions at physiological pH.The composition can be administered intramuscularly or subcutaneously.Other compounds are administered according to standard procedures used by those skilled in the art.

[0082] Pharmaceutical compositions may include, in addition to the molecule of choice, carriers, thickeners, diluents, buffers, preservatives, surfactants, etc. Pharmaceutical compositions may also include one or more active ingredients, such as antibacterial agents, anti-inflammatory agents, anesthetic agents, etc.

[0083] The pharmaceutical composition can be administered in several ways, depending on whether local or systemic treatment is desired and the site to be treated. Administration can be topical (including intraocular, intravaginal, rectal, intranasal), oral, by inhalation, or parenteral, for example, intravenous drip, subcutaneous, intraperitoneal, or intramuscular injection. The disclosed antibodies can be administered intravenously, intraperitoneally, intramuscularly, subcutaneously, intracavity, or transdermally.

[0084] Preparations for parenteral administration include sterile aqueous or non-aqueous solutions, suspensions, and emulsions. Examples of non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate. Aqueous carriers include water, alcoholic / aqueous solutions, emulsions, or suspensions, including saline and buffered media. Parenteral vehicles include sodium chloride solution, Ringer's dextrose, dextrose and sodium chloride, lactated Ringer's, or fixed oils. Intravenous vehicles include fluid and nutrient replenishers, electrolyte replenishers (such as those based on Ringer's dextrose), and the like. Preservatives and other additives may be present, such as, for example, antibacterial agents, antioxidants, chelating agents, and inert gases.

[0085] Formulations for topical administration may include ointments, lotions, creams, gels, drops, suppositories, sprays, liquids, and powders. Conventional pharmaceutical carriers, aqueous, powder or oily bases, thickeners, and the like may be necessary or desirable.

[0086] Compositions for oral administration include powders or granules, suspensions or solutions in water or non-aqueous media, capsules, sachets, or tablets.Thickeners, flavorings, diluents, emulsifiers, dispersing aids, or binders may be desirable.

[0087] Some of the compositions can potentially be administered as pharma- ceutically acceptable acid or base addition salts formed by reaction with inorganic acids such as hydrochloric acid, hydrobromic acid, perchloric acid, nitric acid, thiocyanic acid, sulfuric acid, and phosphoric acid, and organic acids such as formic acid, acetic acid, propionic acid, glycolic acid, lactic acid, pyruvic acid, oxalic acid, malonic acid, succinic acid, maleic acid, and fumaric acid, or with inorganic bases such as sodium hydroxide, ammonium hydroxide, potassium hydroxide, and organic bases such as mono-, di-, tri-alkyl, and aryl amines, and substituted ethanol amines.

[0088] Therapeutic Use Effective dosages and schedules for administering the compositions can be determined empirically, and making such determinations is within the skill of the art. The dosage range for administering the compositions is one that is large enough to produce the desired effect in which the symptoms of the disorder are affected. The dosage should not be so large as to cause adverse side effects, such as undesirable cross-reactions, anaphylactic reactions, and the like. In general, dosages vary according to the age, condition, sex, and extent of the disease of the patient, the route of administration, or whether other drugs are included in the regimen, and can be determined by one of skill in the art. Dosages can be adjusted by the individual physician in the event of any counterindications. Dosages can vary and can be administered in one or multiple doses per day, for one or several days. Guidance can be found in the literature regarding appropriate dosages for a given class of pharmaceutical products. For example, guidance in selecting an appropriate dose of an antibody can be found in the literature on the therapeutic use of antibodies, e.g., Handbook of Monoclonal Antibodies, Ferrone et al., eds., Noges Publications, Park Ridge, NJ, (1985) ch.22 and pp.303-357; Smith et al., Antibodies in Human Diagnosis and Therapy, Haber et al., eds., Raven Press, New York (1977) pp. 365-389. Typical daily dosages of antibodies used alone can range from about 1 μg / kg body weight up to 100 mg / kg body weight or more per day, depending on the factors mentioned above. EXAMPLES

[0089] The following examples are presented for the purpose of providing those skilled in the art with a complete disclosure and description of how the compounds, compositions, articles, devices, and / or methods claimed herein are made and evaluated, and are intended to be purely illustrative and are not intended to limit the present disclosure. Efforts have been made to ensure accuracy with respect to numerical values ​​(e.g., amounts, temperatures, etc.), but some errors and deviations should be accounted for. Unless otherwise indicated, parts are parts by weight, temperature is in ° C. or is at atmospheric temperature, and pressure is at or near atmospheric pressure.

[0090] Example 1: Anti-oncodriver Th1 responses in breast cancer Most breast tumors express onco-drivers, including HER2, EGFR (ER+ and TNBC), c-MET (TNBC), and HER3 (ER+, HER2, and TNBC). These onco-drivers or downstream pathways are often targeted by many therapeutic agents, and patients with metastatic breast cancer (MBC) are often treated with targeted agents, such as antiestrogens, CDK4 / 6 inhibitors, HER2-directed therapeutics, and AKT inhibitors. However, many of these patients become resistant or non-responsive to treatment and progress. Thus, these patients require further treatment. Checkpoint therapies have shown promising but limited efficacy in MBC, so it would be highly desirable to identify effective new immunotherapies that can be combined with targeted agents to be more effective in MBC. As shown by the following data, onco-drivers may be important and relevant targets for immune responses.

[0091] Evidence for loss of anti-oncodriver Th1 responses during tumorigenesis: Healthy adult women have an unusually high pre-existing Th1 immunity to HER2 in the peripheral blood (Figures 1A and 1C; see e.g., Datta J, et al., Oncoimmunology. 2015;4:e1022301; Datta J, et al., Breast Cancer Res. 2015;17:71; and Fracol, M., et al., Ann Surg Oncol (2017) 24: 407. https: / / doi.org / 10.1245 / sl0434-016-5584-6). However, these Tbet pos Th1 cells are gradually lost during tumorigenesis. This loss is first detectable at the ductal carcinoma in situ (DCIS) stage and becomes largely suppressed by the stage I invasive breast cancer (IBC) (Figures 1A, 1C, and 1D). neg There was no such loss of HER2 Th1 immune responses during tumorigenesis (Figure 1A), nor loss of responsiveness to other (nontumor) control antigens (data not shown), indicating that this suppression was antigen-selective and not due to generalized anergy. Although this loss of anti-HER2 Th1 is not routinely corrected by standard treatments of surgery, radiation, and chemotherapy with trastuzumab, vaccination with HER2-pulsed type I dendritic cells (DC1) can dramatically increase peripheral anti-HER2 CD4 Th1, indicating that this is not a fixed defect but instead is correctable by appropriate immunization (Figure 1B). It is unclear whether the decrease in peripheral blood CD4 Th1 represents a true loss of cells or a migration from the central circulation to peripheral sites.

[0092] Anti-HER2 Th1 responses correlate with clinical outcomes: HER2 Achieving Pathological Complete Response (pCR) to Neoadjuvant Chemotherapy (NAC) pos Patients with IBC show improved survival, while those with residual disease at the time of surgery show an increased risk of recurrence. posIBC patients, as a population, show a decline in anti-HER2 Th1 immunity, with some individuals being largely suppressed and others maintaining a moderate level of responsiveness. Patients who regain or partially retain anti-HER2 Th1 show higher pCR rates to neoadjuvant chemotherapy / trastuzumab therapy, whereas patients with residual disease show the lowest anti-HER2 CD4 Th1 responses (Figure 1D). Although a loss of repertoire is shown, there are also significant differences in overall and cumulative responses. Loss of anti-oncodriver CD4 immune responses is associated with a decline in GATA 3 pos Tbet, not Th2 population pos This represents a decrease in interferon gamma (IFN-γ) production in the Th1 population, suggesting that Th1 immune responses may be important for mediating anti-oncodriver BC responses. Indeed, elevated immune gene expression in tumors is associated with improved outcomes. The relationship between anti-HER2 immunity and disease-free survival (DFS) was also examined. Patients who relapsed and experienced reduced DFS exhibited the most diminished anti-HER2 Th1 immune responses (Figure 1F), whereas patients with preserved peripheral anti-HER2 Th1 responses had substantially higher DFS (Figure 1F). This lack of peripheral CD4Th1 may reflect a true loss of immune activity away from the periphery, or a tolerized or exhausted response.

[0093] Example 2: HER2 pos Anti-HER-2 CD4 Th1 boost with DC1 therapy in early stage breast cancer Currently, HER2 pos 2 and HER2 in patients with DCIS posFour clinical trials are ongoing, two in patients with IBC. See Lowenfeld L, et al. Clin Cancer Res. 2017;23:2961-71. All four trials demonstrate that DC vaccination can increase anti-HER2 CD4 Th1 responses in peripheral blood, which does not correlate well with response to treatment, but that administration of DC1 boosts anti-HER2 CD4 Th1. DCIS patients received only weekly vaccine for 4-6 weeks in either the distal inguinal lymph nodes or the DCIS area of ​​the breast, while invasive patients received weekly intranodal injections for the first 6 weeks followed by 3x intranodal boosts for 3 months. 85% of patients showed an increase in anti-HER2 CD4 Th1. In the two DCIS trials in which DC1 was administered in the neoadjuvant setting, ER neg Approximately 30% of patients showed pCR to DC1 vaccination (Figure 2A), whereas ER pos HER2 posFor patients, adding anti-estrogen therapy to DC1 vaccination improved the pCR rate from the minimal background response to a similar level (Figure 2A), indicating the effectiveness of the combination approach. DC1 therapy was effective regardless of whether it was administered to the distant lymph nodes or to the DCIS region of the breast. Interestingly, patients who achieved pCR showed the highest levels of anti-HER2 CD4 Th1 in the sentinel lymph nodes (Figure 2B). This indicates that achieving a significant anti-HER2 CD4 Th1 response in the local area of the tumor results in the strongest clinical response, and the inventors were prompted to further test this in a preclinical model, leading to the current effective treatment method for DC1. Although the number of subjects who achieved pCR with DC1 therapy in DCIS was small, any subsequent breast events (SBE) were expected to decrease very favorably compared to subjects who achieved pCR (Figure 2C), which is important for reducing recurrence and mortality in high-risk DCIS patients. Since it is considered important for reducing mortality, the effects of DC1 therapy and Th1 cytokines on disseminated cancer cells (DCC) were investigated. In patients with IBC T1a / b lesions within DCIS, the rate at which no residual lesions were found at the time of surgery was only about 8%. Although this treatment method has been shown to be promising, it is clear that improvements are needed to be developed as a satisfactory treatment method for patients with HER2-expressing DCIS and T1a / b IBC. Therefore, in order to move forward based on this opportunity, we returned to the preclinical model.

[0094] Example 3: DC1 Vaccine in Combination with SEMA4D Blockade Semaphorin 4D (SEMA4D) is a member of a family of cell surface molecules that are essential for tissue and organ development and are involved in immune regulation. Antibodies against SEMA4D have been shown to regulate lymphocyte infiltration into tumors (see, e.g., U.S. Patent No. 9,243,068). In this example, anti-SEMA4D monoclonal antibody (Mab 67, see, e.g., U.S. Patent No. 8,496,938) was combined with DC1 vaccination in the HER2 mouse TUBO tumor model as follows: The TUBO mouse breast tumor cell line (accession number CVCL_2A33, Rovero, S., et al., J. Immunol 165:5133-5142 (2000)) was first shown to express SEMA4D by immunohistochemistry (Figure 3A). In the single tumor model (Figure 3B1), 2.5e5 TUBO cells were administered subcutaneously into the right flank of Balb / C mice on day 0. When tumors were palpable on day 7, mice were randomized into four groups. Mice received either intraperitoneal control or anti-sema4D antibodies until endpoint, or intratumoral HER2-DC1 once a week for 6 weeks as monotherapy. For combination therapy, mice received anti-sema4D antibodies followed by the first of weekly intratumoral HER2-DC1 injections for 6 weeks. In the bilateral model, mice were administered 2.5 × 10 5Tumor cells / site were injected subcutaneously into both flanks of Balb / c mice (N=6). DCs were generated and matured to DC1 as previously described (Cintolo JA, 2016, Melanoma Res. 2016 Feb;26(l):1-11) and pulsed with neu peptide. BALB / c mice were administered DC vaccine intratumorally once a week for 6 weeks. In animals with two tumor locations, only one of the two tumors was vaccinated. Mab 67 was administered intraperitoneally at a concentration of 10 mg / kg / body weight at weekly intervals. Control mice received isotype control antibody, DC treatment alone or Mab 67. Tumors were measured with calipers every 2-3 days until the endpoint. To compare in vitro measurements, one-way ANOVA (followed by Tukey post-hoc test) was performed. To compare in vivo measurements, the same test was performed using tumor measurements obtained at each time point. Comparisons between the two treatment groups were made using the Mann-Whitney test. All statistical evaluations of the data were performed using GraphPad Prism software. Statistical significance was achieved at p<0.05.

[0095] Systemic administration of anti-SEMA4D antibodies together with intratumoral HER2-pulsed DC1 to mice bearing established TUBO tumors resulted in complete tumor regression of vaccine-treated tumors compared to treatment with anti-SEMA4D antibodies or DC1 alone (Figure 3B1). This was associated with extended survival (Figure 3B2). Intratumoral injection of HER2 DC1 into a single tumor resulted in regression of the contralateral uninjected tumor (Figures 3C1 and 3C2). Further flow cytometry analysis demonstrated enrichment of anti-HER2 CD4 Th1 responses, including reduced myeloid-derived suppressor cell tumor infiltration (Figure 3E), increased CD4 T cell tumor infiltration (Figure 3F), and increased CD4 T cell lymph node infiltration (Figure 3G). The potential relevance to human tumors is highlighted by the fact that SEMA4D was expressed in approximately 60% of human HER2 DCIS or HER2 IBC, as measured by immunohistochemistry (Figure 3D).

[0096] Example 4: Administration of intratumoral HER2-pulsed DC1 and systemic anti-SEMA4D antibody resulted in a strong anti-tumor Th1 response As described in Example 3, spleens were removed from mice cured of TUBO tumors by the combination of systemic administration of anti-SEMA4D antibody and intratumoral HER2-pulsed DC1 therapy, and from control mice vaccinated intratumorally with DC1 vaccine alone or in combination with anti-SEMA4D antibody, and CD4+ T cells were isolated from splenocytes and co-cultured with HER2-pulsed DC1 for 3-4 days, and then expanded in the presence of IL-2 (10U / ml) and IL-7 (20ng / ml) for 3 weeks. Expanded cells from spleens removed from mice vaccinated with HER2-pulsed DC1 alone or in combination with systemic anti-SEMA4D antibody treatment were compared (Figure 4). The data show that CD4 T cells from mice receiving the combination therapy showed approximately 7-fold in vitro expansion compared to approximately 3-fold in vitro expansion in control mice (Figure 4A). CD4 T cells expanded from the spleens of mice receiving the combination therapy also showed strong antigen specificity for the HER2 / neu-derived peptides p5, p435, and p1209 (see, e.g., Jalali et al., Nanomedicine;8 692-701 (2012)) compared to CD4 T cells expanded from mice receiving the DC1 vaccine alone (Figure 4B). Furthermore, CD4 T cells expanded from the spleens of mice receiving the combination therapy showed strong production of IFN-γ, indicating a strong TH1 response (Figure 4C). These results indicate that CD4 T cells from mice treated with HER2-DC1+aSEMA4D were superior in proliferation, function, and specificity compared to T cells from mice vaccinated with HER2-DC1 alone.

[0097] Example 5: DC1 treatment of BALB / c Neu T transgenic mice affects disseminated cancer cells of HER2-expressing breast cancer We tested DC1 vaccine in HER2 patients with residual disease after neoadjuvant chemotherapy / trastuzumab and found that DC1 administration was safe, led to an increase in anti-HER2 CD4 Th1, and no recurrence was observed in 17 patients at a median follow-up of 40 months. As many of these patients destined to relapse harbor disseminated cancer cells (DCC), we wanted to examine the influence of Th1 cytokines and CD4 Th1 cells on DCC. To do so, we utilized the BALB / c Neu T transgenic mouse model. NeuT is a transgenic mouse model of breast cancer in which the mouse mammary tumor virus (MMTV) promoter drives neuT expression and the mice develop spontaneous tumors in the mammary fat pad of female mice. When female BALB-neuT mice reach 21–28 days of age, neuT protein is overexpressed in the mammary gland and areas of atypical hyperplasia begin to form, which progress to intraepithelial carcinoma at approximately day 60 and to invasive carcinoma at days 120–150. Neoplastic changes occur in all mammary glands, albeit asynchronously, so that by about day 120 one or more tumors are palpable, and by about day 230 all 10 mammary glands contain palpable tumors. We and others have demonstrated the presence of disseminated cancer cells that can be identified in several organs before breast cancer appears (Figures 5A and 5B). These HER2+ cytokeratin-positive cells can be detected in bone marrow, lung, and liver from week 9 onwards, where they constitute 10-15% of the cells and are in a fairly low proliferative state as measured by Ki67 (Figure 5C). Although DCCs are present, vaccination of mice with HER2-pulsed DC1 after week 9, prior to the development of breast cancer, reduced DCCs and also reduced Ki67 expression (Figure 6A). DC1 vaccination reduced breast cancer development at week 16 (Figure 6B). A reduced number of DCCs (Figure 6C) and an increase in markers of tumor senescence were also observed in DCCs from DC1-treated Neu T mice. β-galactosidase expression, a general marker of senescence, is shown in FIG. 6D.These latter data indicate that, in addition to the therapeutic impact on primary or metastatic disease, intratumoral treatment may allow DC1 to drive senescence through the induction of anti-HER2 CD4 T cells, prevent tumor initiation, and impact BC mortality.

[0098] Example 6: Immune cell infiltration following DC1 or SEMA4D treatment BALB-neu transgenic (Neu T) mice were cultured at 1 × 10 6 The mice were treated with subcutaneous injections of rat neu peptide-pulsed DC1 twice weekly or with anti-SEMA4D antibody at a concentration of 10 mg / kg / body weight administered once weekly. At week 16, mice were sacrificed and mammary glands were harvested. Single cell suspensions of mammary glands were prepared and stained for CD19 positive B cells, then analyzed by flow cytometry. Elevated levels of CD19+ B cells were observed in DC1-vaccinated and anti-SEMA4D antibody-treated mice compared to untreated controls, suggesting infiltration of B cells into the mammary gland (Figure 7A). The accumulation of B cells in the tumor area indicates that anti-tumor antibodies play a role in causing the effects seen with DC1 therapy with SEMA4D. In addition, bone marrow cells from control and DC1-vaccinated NeuT mice were stained for CD4 and CD8 T cell markers and analyzed by flow cytometry. Increased numbers of CD4 and CD8 T cells were observed in the bone marrow of DC1-vaccinated NeuT mice compared to untreated control mice (Figure 7B).

[0099] Example 7: IFN-γ and TNF-α from CD4 Th1 induce tumor senescence in HER2-expressing breast cancer Since CD4 and B cells (MHC class II APCs) accumulate around DCIS ducts, we investigated the effect of Th1 cytokines on HER2 BC cells. IFN-γ and TNF-α cause the induction of both apoptosis and tumor senescence in HER2-expressing BC cells. The therapeutic benefit of blocking HER2 / HER3 signaling in breast cancer has been demonstrated both in vitro and in clinical trials. We explored the senescent and apoptotic effects of Th1 cytokines in highly and moderately HER2-expressing cell lines blocked with HER2 and HER3 siRNA (Figure 2). Although combined treatment of TNF-α and IFN-γ in HER3 knockdown SK-BR-3 cells did not significantly increase the number of senescent cells, higher SA-β-gal staining was observed in cells treated with dual HER2 / HER3 knockdown in combination with Th1 cytokines (Figure 8A). Trastuzumab, a humanized recombinant monoclonal antibody against the extracellular subdomain IV of HER2, inhibits ligand-independent dimerization, blocks downstream growth signaling pathways, and induces antibody-dependent cellular cytotoxicity (ADCC). Pertuzumab, another humanized recombinant monoclonal antibody targeting the extracellular subdomain II of HER2, prevents ligand-dependent heterodimerization with other members of the HER family, inhibits growth signaling pathways, and induces ADCC. Both antibodies act in a complementary manner. Using TNF-α and IFN-γ treatment with trastuzumab and pertuzumab, we applied our paradigm of Th1 cytokine-induced senescence and apoptosis to a combination model. HER2-high SK-BR-3 cells showed no significant difference in SA-β-gal staining (Figure 8B, p<0.001) and p15 INK4b Expression (cyclin-dependent kinase 4 inhibitor B, p15 INK4bWe found that senescence was synergistically increased in cells treated with the combination of cytokines and antibodies compared to untreated cells, cells treated with cytokines alone, or cells treated with antibodies alone, as measured by senescence-induced senescence (also known as senescence-induced senescence) (Figure 8C). Notably, the combination treatment not only resulted in a relatively higher percentage of blue senescent cells, but also significantly reduced the overall cell number. An additive increase in apoptosis was demonstrated by an increase in active caspase-3 expression (Figure 8C), as well as an increase in Annexin V and propidium iodide positive cells (Figures 8D and E). We explored the possibility that TNF-α and IFN-γ could induce senescence and apoptosis in trastuzumab- and pertuzumab-resistant cell lines. Treatment of HCC-1419 and JIMT-1 cells with trastuzumab and pertuzumab did not induce senescence or apoptosis (Figure 9). However, dual treatment with cytokines and targeted therapy significantly reduced the expression of p15 in the SA-β-gal assay (Figure 9A) and in HCC-1419 cells (Figure 9B) and JIMT-1 cells (Figure 9C). INK4b Th1 cytokines in combination with HER2 / HER3 blockade can induce tumor senescence and apoptosis even in cell lines resistant to trastuzumab and pertuzumab.

[0100] Next, anti-HER2 CD4 Th1 cells were cultured on HER2 pos We tested whether HER2 peptides could affect BC cells. SK-BR-3 breast cancer cells co-cultured with CD4+ T cells from breast cancer patients stimulated with class II HER2 peptides showed SA-β-gal staining (Figure 10A) as well as p15 INK4bCD4+ T cells stimulated with either immature dendritic cells (CD4+ - DC H (2)) or mature DC+irrelevant class II peptides (BRAF:CD4+ - DC B (5); or survivin:CD4+ - DC S (6)) were unable to induce senescence or apoptosis of SK-BR-3 cells. Similar to the previously demonstrated synergy, the addition of trastuzumab and pertuzumab (4) to the cultures reduced SA-β-gal staining (Figure 10A, p<0.001) as well as p15 expression. INK4b Senescence and apoptosis were significantly enhanced, as evidenced by CD4+-DC H TP, 4 and cleaved caspase-3 expression (Fig. 10B). These results indicate that anti-HER2 CD4 Th1 cells do not have to interact directly with tumor cells, but rather with antigen-presenting cells (APCs) in the TME, and Th1 cytokines can work synergistically with HER2-targeted therapy. This may underlie the possibility that DC1s can be pulsed and bound in the tumor environment to drive anti-HER2 CD4 Th1 responses, and that antibodies such as HPs may work synergistically with Th1 cytokines to eliminate tumor cells.

[0101] Example 8: Clinical activity of Th1 cytokines (IFN-γ) in HER2 breast cancer We have built on the preclinical findings by developing a Phase I / II study to examine whether IFN-γ can be safely administered and have an effect on clinical response. A Phase I study demonstrated that IFN-γ administered subcutaneously three times a week with THP is safe and results in partial response disease stabilization in patients with first-line metastatic BC (Figure 11). This is now moving to a Phase II study administered to patients with >T2 ER+HER2+ IBC in the neoadjuvant setting. Currently, 15 patients have been enrolled, with 2 of the first 4 patients achieving pCR. This gives us hope, as patients with this subtype treated with PTCH, a significantly more toxic regimen, show a pCR rate of approximately 27%. As shown herein, this regimen has been successful in at least maintaining the established pCR rate, and thus this regimen may replace more toxic regimens with simpler and potentially more effective regimens using a combination of Th1 cytokine immunotherapy and standard treatment. We are currently determining whether the DC1 vaccine can drive similar responses in neoadjuvant HER2 patients and drive pCR in combination with PTCH. These data point to the clinical benefit of Th1 cytokines such as IFN-γ influencing HER2 tumors and poised to become a component of a true non-chemotherapeutic regimen for HER2 BC.

[0102] Example 9: Accumulation of B and T cells occurs in patients responding to HER2-pulsed DC1 vaccine Patients who achieve pCR do not show residual DCIS ducts in the breast, but many of them have residual disease, providing an opportunity to evaluate the response in the breast of patients with residual disease. Breast response is often heterogeneous with areas of dense lymphocytic infiltration (Figures 12A and B) and areas of little or no response (Figures 12C and D). Lymphocyte accumulation shows a large percentage of CD4 T cells, as well as CD20+ B cells and some CD8 T cells (Figure 13). These structures mimic the ectopic lymphoid structures associated with good responses. In patients with significant accumulation of these lymphoid structures in and around DCIS ducts, dying or dead ducts are often found, indicating that an immune response is causing the death and elimination of DCIS (Figure 14).

[0103] Effects of anti-SEMA4D antibodies on the TME and tumor vasculature: SEMA4D has been described as a promoter of tumor angiogenesis and has therefore been associated with tumor progression (see, for example, Zhou, et al. Methods Mol. Biol 1493:429-441 (2017)). To study how SEMA4D modifies the TME, particularly tumor vascularization, tumor vascularization in mice injected with TUBO cells as described in Example 3 was observed by in vivo MRI. Dynamic contrast imaging (DCE)-MRI was used to investigate different characteristics of tumor vascularization: area under the curve (AUC), slope, and time to maximum were used to determine the status of tumor vascularization. Gadavist was injected at 0.2 mmol / kg through the tail vein to investigate how single treatment with DC1 alone or anti-SEMA4D alone, or both agents in combination, affected tumor vascularization and tumor regression. In mice that received the combination therapy, smaller gradients, less accumulation of contrast agent, and less vascular leakage were observed compared to untreated or monotherapy (Figure 15 A and B). This data indicates that combination therapy with intratumoral DC1 and systemic administration of anti-SEMA4D antibody improved tumor vascularization, as indicated by smaller gradients and less accumulation of contrast agent and less vascular leakage, which may play a role in inducing complete tumor regression in both single and bilateral TUBO models.

[0104] Example 10: Effect of Anti-SEMA4D on Tumor pH Effect of anti-SEMA4D on tumor pH: Because tumors have been shown to be acidic, and tumor acidosis correlates with poor prognosis and is highly dependent on vascular proliferation to reduce its acidity, tumor pH was examined by chemical exchange saturation transfer (CERST)-MRI experiments. As shown in Figure 16, treatment with SEMA4D alone was observed to have the effect of shifting tumor pH from acidic to alkaline over time.

[0105] The above-mentioned murine monoclonal antibody Mab 67 is disclosed, for example, in US Pat. No. 8,496,938.

[0106] The amino acid sequences of the VH and VL genes of MAb 67 are shown below with the CDR1, CDR2, and CDR3 regions underlined. TIFF0007579284000001.tif52161

[0107] 1. Mab VX15 / 2503 (pepinemab) is a humanized version of MAb 67 and is also disclosed in US Patent No. 8,496,938. The amino acid sequence of VX15 / 2503 is reproduced below. TIFF0007579284000002.tif52161

[0108] Example 11: Depletion of CD4+ T cells abolishes anti-SEMA4D activity both alone and in combination with DC-1 treatment Overall, CD4+ T cells play a major role in initiating and shaping adaptive immune responses. To study whether CD4+ T cells are required for clinical responses to the combined HER2 DC1 vaccine / anti-SEMA4D treatment, CD4-depleted tumor-bearing mice were generated and the immune response to treatment was compared to that of non-CD4-depleted ("normal") tumor-bearing mice.

[0109] Balb / C mice were injected with 2.5e5 TUBO cells subcutaneously in the right flank on day 0. When tumors were palpable on day 7, mice were randomized into 4 groups. Mice received either monotherapy with IgG isotype control antibody or anti-SEMA4D antibody / MAb67 (10mg / kg / body weight) intraperitoneally until endpoint, or 1e6 / 100μl intratumoral HER2-DC1 once a week for 6 weeks. For combination therapy, mice received anti-sema4D antibody followed by the first of 6 weekly intratumoral HER2-DC1 injections.

[0110] CD4-depleted Balb / C mice were generated by intraperitoneal administration of 300 μg of anti-CD4-depleting antibody (clone GK1.4) starting 3 days prior to TUBO tumor implantation, and treatment with anti-CD4 antibody continued with two injections per week until endpoint (see Evans, EE, et al. (2015). Cancer Immunol Res 3(6): 689-70). CD4-depleted mice were treated with monotherapy, anti-SEMA4D antibody / MAb67, or combination therapy as described above for tumor-bearing non-CD4-depleted mice.

[0111] The mean tumor volume and survival rate of each group are shown in Figures 17A-D (17A and B (control, no CD4 depletion; tumor volume and survival rate, respectively) and 17C and D (CD4 depletion)). Figures 17E (control, no CD4 depletion) and 17F (CD4 depletion) show the tumor growth curves of each mouse. Complete tumor regression was observed after treatment with anti-SEMA4D, and activity was further enhanced with combination therapy. All combination-treated mice from the non-depleted group survived the 60-day study period (Figure 17B), and 4 / 5 of these mice showed complete tumor regression. (Figure 17E). However, depletion of CD4+ T cells completely abolished the activity of anti-SEMA4D treatment, both alone and in combination with DC-1 vaccine (Figure 17D). These data indicate that CD4+ T cells are required for a clinically effective response to anti-SEMA4D therapy.

[0112] Example 12. Role of Fc gamma receptors (FcγR) in the clinical efficacy of combination therapy The FcγR-mediated functions most commonly associated with therapeutic antibodies are those that mediate target cell elimination-antibody-dependent cellular cytotoxicity (ADCC), a cell-mediated mechanism of immune defense in which effector cells of the immune system actively lyse target cells whose membrane surface antigens have been bound by specific antibodies. These functions are triggered when antibody binding to antigens on the surface of target cells generates sufficient avidity to trigger signaling through FcγRs on effector cells, such as NK cells and macrophages, which then eliminate the target cells through direct killing or phagocytosis. Preclinical models indicate that this form of FcγR-mediated cytotoxicity is an important component of the mechanism of action of certain tumor-targeting antibodies (Clynes RA et al., Inhibitory Fc receptor modulate in vivo cytoxicity against tumor targets. Nat Med. 2000, 6: 443-446).

[0113] To study the role of FcγR in clinical response to combination therapy, FcγR knockout mice were generated. Briefly, this model was generated by targeted disruption of the Fcer1g gene by introducing a new stop codon in E14 ES cells and injecting the targeted cells into C57BL / 6 blastocysts. Heterozygotes on a C57BL / 6 background were crossed to generate homozygous targeted mutant mice. These mice were then backcrossed for 12 generations to a BALB / cByJ inbred background (N12). (Takai T, Li M, Sylvestre D, Clynes R, Ravetch J. (1994) FcRγ Chain Deletion results in Pleiotrophic Effector Cell Defects.).

[0114] On day 0, 2.5 x 10 5 Tumor cells / site were cultured in BALB / C- Fcer1g KO mice (C.129P2(B6)-Fcer1g tm1RavN12) were injected subcutaneously into both flanks of mice. DCs were generated, matured to DC1, and pulsed with MHC class II neu peptide. Mice were administered 1e6 / 100 μl DC1 vaccine intratumorally once a week for 6 weeks. In animals with two tumor locations, only one of the two tumors was vaccinated. Anti-SEMA4D Mab 67 was administered intraperitoneally at a concentration of 10 mg / kg / body weight at weekly intervals. Control mice received isotype control antibody, DC treatment alone, or Mab 67. Tumors were measured with calipers every 2-3 days until the endpoint. The mean tumor volume and survival rate of treated tumors for each group are shown in Figure 18A and Figure 18B, respectively. Tumor growth curves for each mouse are shown in Figure 18C. (CR=complete tumor regression; tumor volume <50 mm 2 ).

[0115] The data show that in mice lacking Fc receptor gamma expression, combination therapy significantly delayed tumor growth compared to no treatment or single agent treatment (Figure 18A and B). However, in contrast to control mice treated with combination therapy (Figure 17E), complete tumor regression was not achieved (Figure 18B), indicating that Fc receptor gamma is essential for the complete antitumor efficacy of combination therapy.

[0116] Example 12. Role of IFN-γ on the clinical efficacy of combination therapy Interferon-gamma (IFN-γ) is a pleiotropic molecule that has been implicated in antiproliferative, proapoptotic, and antitumor mechanisms. This effector cytokine is considered to be the primary effector of immunity and is a key Th1 cytokine associated with antitumor immune responses.

[0117] To study the role of IFN-γ in the clinical response to combination therapy, Balb / C IFN-gamma knockout (KO) (C.129S7 (B6)-IFNg tm1Ts / J (IFN-γ KOTumors were developed in mice (Jackson Laboratories, Jackson Laboratories). On day 0, 2.5e5 TUBO cells were administered subcutaneously to the right flank of the mice. Dendritic cells were generated, matured to DC1, and pulsed with MHC class II neu peptide. On day 7, when they were palpable, mice were randomized into 4 groups. Mice received either control or anti-sema4D antibodies (10 mg / kg / body weight) intraperitoneally until endpoint, or 1e6 / 100 μl intratumoral HER2-DC1 once a week for 6 weeks as monotherapy. For combination therapy, mice received anti-sema4D antibodies followed by the first of 6 weekly intratumoral HER2-DC1 injections. Tumors were measured with calipers every 2-3 days until endpoint. The mean tumor volume for each group is shown in Figure 19.

[0118] The data demonstrate that the antitumor activity of DC1, anti-SEMA, and the combination requires IFN-γ for activity. These results are similar to those obtained with CD4 depletion of immunocompetent mice (Figure 17), demonstrating that both IFN-γ and CD4 cells are required for the antitumor response to anti-SEMA4D therapy.

Claims

1. (i) at least one dendritic cell pulsed with a human epidermal growth factor receptor 2 (HER2) oncodriver and formulated for intratumoral administration; (ii) at least one immunomodulatory molecule inhibitor comprising an antagonist antibody or an antigen-binding fragment thereof and formulated for systemic administration; A combination drug for treating cancer comprising: The above combination pharmaceutical, wherein the antagonist antibody or antigen-binding fragment thereof specifically binds to semaphorin 4D (SEMA4D).

2. The combination pharmaceutical described in claim 1, wherein the dendritic cells pulsed with a HER2 oncodriver are activated with IL-12 prior to administration.

3. The combination pharmaceutical of claim 1, wherein the antagonist antibody that specifically binds to SEMA4D comprises pepinemab.

4. A combination pharmaceutical described in any one of claims 1 to 3, wherein at least one dendritic cell pulsed with a HER2 onco-driver is obtained by harvesting dendritic cells from a subject to be treated with the anti-cancer combination therapy and is pulsed with a HER2 onco-driver ex vivo.

5. The pharmaceutical combination according to any one of claims 1 to 4, wherein the cancer is breast cancer, melanoma, colorectal cancer, pancreatic cancer, prostate cancer, bladder cancer, ovarian cancer, gastric cancer, any combination thereof, or any metastasis thereof.

6. A combination pharmaceutical described in any of claims 1 to 5, wherein the antagonist antibody or antigen-binding fragment thereof that specifically binds to SEMA4D comprises a heavy chain variable domain (VH) including VH CDR1-3 having the amino acid sequences SEQ ID NO: 5, 6, and 7, respectively, and a light chain variable domain (VL) including VL CDR1-3 having the amino acid sequences SEQ ID NO: 8, 9, and 10, respectively.

7. The combination pharmaceutical of claim 6, wherein the antagonist antibody or antigen-binding fragment thereof that specifically binds to SEMA4D comprises a VH and a VL having the amino acid sequences SEQ ID NO: 3 and SEQ ID NO: 4, respectively.

8. 1. Use of (i) at least one dendritic cell pulsed with a HER2 onco-driver and (ii) at least one immunomodulatory molecule inhibitor in the manufacture of a combination medicament for treating cancer, comprising: The above use, wherein the at least one immune modulator molecule inhibitor comprises an antagonist antibody or an antigen-binding fragment thereof, and the antagonist antibody or an antigen-binding fragment thereof specifically binds to semaphorin 4D (SEMA4D).

9. The use described in claim 8, wherein the dendritic cells pulsed with a HER2 oncodriver are activated with IL-12 prior to administration.

10. The use of claim 8, wherein the antagonist antibody that specifically binds to SEMA4D comprises pepinemab.

11. The use according to any one of claims 8 to 10, wherein the at least one immunomodulatory molecule inhibitor is formulated for systemic administration.

12. The use described in any one of claims 8 to 11, wherein at least one dendritic cell pulsed with a HER2 onco-driver is formulated for intratumoral administration.

13. The use described in any one of claims 8 to 12, wherein at least one dendritic cell pulsed with a HER2 onco-driver is obtained by harvesting dendritic cells from a subject to be treated with an anti-cancer combination therapy and pulsed with a HER2 onco-driver ex vivo.

14. 14. The use according to any one of claims 8 to 13, wherein the cancer is breast cancer, melanoma, colorectal cancer, pancreatic cancer, prostate cancer, bladder cancer, ovarian cancer, gastric cancer, any combination thereof, or any metastasis thereof.

15. The use of any of claims 8 to 14, wherein the antagonist antibody or antigen-binding fragment thereof that specifically binds to SEMA4D comprises a heavy chain variable domain (VH) comprising VH CDR1-3 comprising the amino acid sequences SEQ ID NOs: 5, 6, and 7, respectively, and a light chain variable domain (VL) comprising VL CDR1-3 comprising the amino acid sequences SEQ ID NOs: 8, 9, and 10, respectively.

16. The use described in claim 15, wherein the antagonist antibody or its antigen-binding fragment that specifically binds to SEMA4D comprises a VH and a VL comprising the amino acid sequences SEQ ID NO: 3 and SEQ ID NO: 4, respectively.

17. A pharmaceutical composition for treating cancer comprising at least one immune modulatory molecule inhibitor comprising an antagonist antibody or antigen-binding fragment thereof and formulated for systemic administration, wherein the antagonist antibody or antigen-binding fragment thereof specifically binds to semaphorin 4D (SEMA4D), and the pharmaceutical composition is used in combination with at least one dendritic cell pulsed with a human epidermal growth factor receptor 2 (HER2) onco-driver and formulated for intratumoral administration.

18. A pharmaceutical composition for treating cancer comprising at least one dendritic cell pulsed with a human epidermal growth factor receptor 2 (HER2) oncodriver and formulated for intratumoral administration, wherein the pharmaceutical composition is used in combination with at least one immune modulatory molecule inhibitor comprising an antagonist antibody or its antigen-binding fragment and formulated for systemic administration, wherein the antagonist antibody or its antigen-binding fragment specifically binds to semaphorin 4D (SEMA4D).

Citation Information

Patent Citations

  • Use of semaphorin-4d inhibitory molecules in combination with immunomodulatory therapy to inhibit tumor growth and metastasis

    JP2016528195A

  • Manufacture of multi-dose ready-to-inject dendritic cell vaccines

    JP2018515421A